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Abstract. Colloidal gold is undoubtedly one of the most extensively studied nanomaterials, 
with 1000s of different protocols currently available to synthesise gold nanoparticles 
(AuNPs). While developments in the synthesis of AuNPs have progressed rapidly in recent 
years, our understanding of their biological impact, with particular respect to the effect of 
shape, size, surface characteristics and aggregation states, has struggled to keep pace. It is 
generally agreed that when AuNPs are exposed to biological systems, these parameters 
directly influence their pharmacokinetic and pharmacodynamic properties by influencing 
AuNPs distribution, circulation time, metabolism and excretion in biological systems. 
However, the rules governing these properties, and the science behind them, are poorly 
understood. Therefore, a systematic understanding of the implications of these variables at 
the nano-bio interface has recently become a topic of major interest. This Review Article 
attempts to ignite a discussion around the influence of different physico-chemical parameters 
on biological activity of AuNPs, while focussing on critical aspects of cellular interactions, 
uptake and cytotoxicity. The review also discusses emerging trends in AuNPs uptake and 
toxicity that are leading to technological advances through AuNPs-based therapy, diagnostics 
and imaging. 
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1. Introduction 
The use of gold to promote good health has been extensively documented in literature dating 
back to the 1st century [1-5], however it was not until 1856 that Faraday’s pioneering work 
set the foundation of modern colloidal chemistry, or rather, nanotechnology [6]. It is now 
well known that as a particle decreases in size towards the nanoscale (Fig. 1), its inherent 
properties do not necessarily reflect the properties of the bulk material it is derived from, nor 
that of its individual atoms – this is indeed the case with gold nanoparticles (AuNPs) [7-12]. 
Generally speaking, as particle size decreases, the proportion of atoms which are localised on 
the particle surface grows, compared to those confined to the inside of the particle [13]. This 
effect gives rise thermal, optical, electrical, magnetic, electronic and catalytic properties [13-
31]. 
In the case of metal nanoparticles, particularly, gold, silver and copper, when particle size 
becomes significantly small relative to the wavelength of light, the large number of surface 
electrons lead to interesting phenomena such as surface plasmon resonance (SPR) [32-35]. In 
the case of spherical AuNPs with sizes less than 60 nm, the SPR peak absorbance appears at 
around 520 nm, accounting for the ruby red colour commonly attributed to AuNPs [36]. 
Modifications to the size, shape and chemical environment of the particles alter the position 
of the plasmon band, and hence the apparent colour of the particles in solution [37-40]. It is 
this phenomenon which explains the use of AuNP suspensions throughout history to create 
the spectrum of colours possible in stained glass [9, 32, 36, 41, 42]. While size and chemical 
environment influence the position of plasmon bands of AuNPs, the nanoparticle shape offers 
better opportunities to controllably fine-tune the optical properties of these materials [43, 44]. 
For instance, spherical AuNPs possess limited potential for SPR tuning as the intensity and 
position of the absorption bands are relatively fixed with only a small red shift and 
4		
	
broadening seen with increasing particle size [37]. Conversely, altering the distance along 
which the oscillations are permitted to occur [45], which is achieved through altering the 
shape of AuNPs, gives rise to interesting optical properties that span the broader visible to 
near-infrared spectrum, making them more suitable for biological sensing, imaging and even 
therapy [46-54]. 
 
Fig. 1. Depicting the nanoscale relative to other objects. 
Considering the interesting optical properties of AuNPs and their perceived biocompatibility 
[55, 56], there has been significant interest in elucidating the interactions of AuNPs with 
biological systems, however much of this work pertains to spherical AuNPs. Further, it is 
commonly thought that changes in particle shape and size could influence the way that 
particles are recognised, processed and excreted by the body, however this conjecture 
remains largely untested [48, 49, 57-62]. Notably, when AuNPs are exposed to biological 
systems, their surface features such as the presence of capping agents, unreduced metal ions 
and surface charge, can directly dictate the pharmacokinetic and pharmacodynamic properties 
of the nanoparticle [63-65], making it difficult to draw valid conclusions by simply 
comparing the biological activities of AuNPs originating from different laboratories. 
Therefore, a systematic understanding of the implications of these variables at the nano-bio 
interface has recently become a topic of major interest [65]. This Review article is an attempt 
to ignite a critical discussion around the influence of different physico-chemical parameters 
on the biological activity of AuNPs (Fig. 2). 
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Fig. 2. Different physico-chemical properties of AuNPs that may influence their interaction 
with the biological systems. 
While concerns exist regarding the practicality of utilising AuNPs in vivo due to potential 
metal accumulation in the body, such concerns have not been thoroughly tested through long-
term in vivo studies [66]. It is only recently that the importance of such studies has been 
recognised, and the research community has more seriously started to investigate the 
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influence of in vivo factors, such as spontaneous protein corona formation on nanoparticle 
surfaces in response to exposure to the biological fluids [67, 68]. New knowledge gained 
from nanoparticle-protein dynamic interactions will determine the way forward for tailoring 
AuNP-based systems for in vivo applications, and it will also offer equally valuable 
opportunities to take in vitro applications of AuNPs, such as diagnostics, to a 
commercialisation stage. This Review Article will therefore critically review various AuNP 
synthesis methods, assess relevant biological studies to highlight emerging trends in AuNPs 
uptake and toxicity, and highlight future directions for the application of AuNPs for 
biomedical investigations.  
2. Synthesis of gold nanoparticles 
While Faraday first described the reduction of tetrachloroauric(III) acid (HAuCl4) to form 
colloidal gold suspensions in 1857 [6], the most popular method still used today was devised 
by Turkevich et. al., in 1951 [69]. During the reaction, which yields ~ 20 nm gold spheres, 
HAuCl4 is brought to a boil at which point a solution of trisodium citrate dehydrate is added. 
During the procedure described by Turkevich, as well as most other in situ methods of 
spherical AuNP synthesis, the reaction has two main stages, viz. nucleation and growth that 
seem to occur concurrently [70]. The first step in the Turkevich reaction involves citrate 
being oxidised to form dicarboxyacetone, while in parallel Au3+ ions are reduced to Au1+ ions 
and subsequently to Au0 atoms. Following this step, gold atoms are generated from the 
disproportionation of aurous chloride molecules which can accommodate the adsorption of 
gold ions on their surface to form aggregates. During this process dicarboxy acetone acts as 
an “organiser” molecule to facilitate many of the steps of this reaction [71]. This synthesis 
has been subsequently adapted by many researchers to allow for size control [72], and varied 
chemical methods have been developed by later groups [73-76]. While all chemical methods 
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must have a component which reduces gold as well as a component to provide stabilisation of 
the newly formed particles, these chemicals can vary greatly leading to the creation of vastly 
different particles with chemically different surface species [70]. 
The use of stabilisers is of great importance in shape-controlled synthesis of AuNPs, and a 
range of stabilisers have been employed to achieve the many shapes researchers seek for 
various applications. Generally, shape controlled synthesis is performed through a seed-
mediated growth process, wherein the nucleation and growth steps do not occur in parallel. 
Separating the two steps allows for tighter control over morphology and is generally favoured 
for larger spherical particles and AuNPs of different shapes [70]. The process begins by 
preparing small (<10 nm) spherical gold seed particles [77-79]. These seed particles are then 
added to a growth solution, typically containing a weak reducing agent, a stabilising agent 
and additional gold ions. While the seed particles added to the growth solution act as a 
catalyst for the reduction of the unreacted gold ions, the weak reducing agent in the presence 
of an appropriate stabiliser allows Au0 nanocrystals to be further grown in specific 
morphologies [70]. 
While chemical methods of nanoparticle synthesis are commonly employed due to their 
relative convenience, non-chemical or pseudo-chemical means of creating nanomaterials also 
exist. Reducing gold ions without the use of a chemical reductant eliminates the presence of 
‘contaminants’ or chemicals precursors which alter the nature of the particle surface. For 
instance, photochemical synthesis methods harness the energy of ultra-violet radiation to 
induce reduction of gold ions producing uniform spherical particles. This is possible as the 
rate of reduction can be controlled by the level of radiation [80].  
Conversely, laser ablation is described as a “top-down” technique as the starting materials for 
synthesis are bulk materials, typically foils, pellets, or even liquids (Fig. 3). Top-down 
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methods involve the removal of nanoscale material from a bulk surface, in this case, with the 
use of laser light. As with all synthesis routes, there are inherent disadvantages and 
limitations associated with laser ablation, including relatively low yield when compared with 
other methods as well as difficulties associated with shape and size control [81]. This is in 
part due to the absence of a stabilising agent, thus if the AuNP concentration exceeds a 
certain limit, the particles tend to agglomerate and collapse in the solution. 
 
Fig. 3. Schematic depicting the two main approaches to nanoparticle synthesis. 
Additionally, a number of biological methods have been reported for the synthesis of 
nanoparticles of gold and other inorganic materials [53, 82-98]. These methodologies rely on 
the unique ability of certain microorganisms, plant extracts and biomolecules to produce 
nanoparticles. The biological approach of nanoparticle synthesis takes advantage of certain 
classes of biochemicals such as enzymes, oxidisable species, amino acids, etc. to allow these 
organisms to produce nanomaterials on exposure to appropriate chemical precursors [99-
9		
	
101]. Since these biochemical species involved in nanoparticle synthesis are produced in situ 
by the organisms, the biological synthesis of nanoparticles may be considered as a pseudo-
chemical approach. Further understanding about biological synthesis of nanoparticles can be 
obtained from some of the reviews recently published in this area [102-107]. 
2.1 Size controlled synthesis of gold nanoparticles 
Many years after Turkevich published his method of AuNP synthesis, Frens identified the 
ratio of gold salt to trisodium citrate as the defining factor governing AuNP size. The method, 
which allowed synthesis of particles up to 150 nm in size, was achieved by simply modifying 
the amount of trisodium citrate in the reaction; reducing levels to create larger particles [72]. 
This is possible because while there is sufficient sodium citrate to reduce the gold ions 
slowly, there is less available oxidised sodium citrate to act as a stabiliser to cap the particles 
and prevent further growth. The disadvantage to this process is that as the particles get 
bigger, they also become more polydisperse due to the parallel formation of new Au nuclei 
while pre-existing Au nuclei grow in size. In contrast, stronger reducing agents such as 
sodium borohydride provide a seemingly instant reduction of gold ions under ambient 
conditions, yielding smaller and less polydisperse particles compared to those achieved by 
sodium citrate [70]. While Frens pioneered the size control synthesis of AuNPs, the 
polydispersity of particles over 30 nm was significant and thus other methods for size control 
were developed. Another chemical method for increasing the size of spherical AuNPs 
involves seed mediated growth (originally called “germ-growth”), as described by Schmid et 
al. [108]. Using this approach, small AuNPs (such as those obtained using the Turkevich 
method) are used as nucleation sites for the growth of larger particles. The size of the final 
particles could be tuned by varying 3 factors; the diameter of the initial seed particles, the 
amount of seed added to the growth solution, and the amount of ionic gold present in the 
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growth solution. However the size of the seed particles is of great importance, as this factor 
dictates the attainable size range of the final particles. While it is theoretically possible to 
employ this method to produce AuNPs ranging in size from 14-900 nm, the difficulty in 
synthesising seeds of low polydispersity in very small and very large size domains meant that 
the extreme ends of the size spectrum became difficult to control. 
An advancement to this type of seed mediated approach was developed by Sau et al., who 
combined the traditional chemical method with a photoirradiation technique first shown by 
Esumi et al. [109] and Itakura et al. [110] in 1995, and later by Zhou in 1999 [111]. Though 
the method was utilised by the initial research groups for shape control, it was hitherto not 
exploited as a means for controlling the size of spherical AuNPs. The new method eliminated 
the difficulty of synthesising monodisperse seed particles via chemical methods, replacing it 
with a method of seed production which proceeds via photoirradiation of chloroauric acid and 
Triton X-100 (poly(oxyethylene)iso-octylphenyl ether)) with UV light [112]. By varying the 
ratios of gold ions to Triton X-100 (the stabiliser/reductant) in the system the seed particles 
could be tuned between 5-20 nm with low polydispersity. While only capable of attaining 
sizes between 5-110 nm, these seed particles could then be used in a manner similar to 
Schmid et al., but with increased control over AuNPs at the smaller end of the size scale.  
In 2001, the same year as the previously described Sau et al. method was published; Jana and 
co-workers published a method for synthesising AuNPs ranging in size from 5-40 nm [113]. 
In contrast to other methods, one seed particle, i.e., 3.5 nm citrate-capped, NaBH4-reduced 
AuNPs was utilised initially, however the reaction was an iterative growth process with the 
particles obtained from one growth reaction being used to seed another and so on, creating 
larger particles with each growth step (Fig. 4). The range of sizes was also affected by 
varying the ratio of gold seeds to metal salt in the growth solutions.  
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Fig. 4. TEM images of AuNPs prepared by using an iterative seed mediated approach. 
Particle size ranges from (a) 5.5 nm, (b) 8.0 nm, and (c) 17 nm to (d) 37 nm. Reprinted with 
permission from [113]. Copyright 2001 American Chemical Society.  
While seed mediated processes (both iterative and non-iterative) have been used by many 
groups [114-117], there are additional methods for producing different sized spherical AuNPs 
which do not involve seed mediated growth. 
Biological methods for producing various sized AuNPs have also been exploited, such as the 
use of plant extracts by Song et al. Using aqueous broths obtained by boiling the leaves of 
Magnolia (M. kobus) and Persimmon (D. kaki) plants in water as reducing agents, the group 
experimented with temperature and leaf broth concentrations to study the effect of these 
variables on AuNPs size. They noted that smaller particles were obtained (as well as a faster 
reaction time) with increasing temperature. For instance, 40 nm particles formed at 95 °C 
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compared to 110 nm particles at room temperature, while leaf broth concentration had greater 
effect on the morphology of the particles rather than their size [118]. 
Organoamine-protected AuNP synthesis methods were introduced by Jana et al. in 2003 [5] 
and later refined by Hiramatsu et al. in the following year [119]. The simplified reaction 
involves refluxing a solution of HAuCl4 and oleylamine (9-octadecenylamine) in toluene for 
2 hours. These nanoparticles differ from those produced by chemical methods as they are 
isolated via precipitation to yield a stable powdered sample which can easily tolerate surface 
modification allowing solubility in water or organic solvents. While the size range achievable 
is admittedly narrow, confined to 6-21 nm, the AuNPs were very stable, and the process by 
which they were synthesised is simple and can be readily scaled up. In this reaction the 
particle size is mainly dependant on the concentration of the gold salt with greater gold 
concentrations producing smaller particles. Conversely, the concentration of amine within the 
reaction primarily controls the polydispersity of the particles, with polydispersity decreasing 
with increased amine concentration. 
In general, it may be noted that size control of spherical AuNPs is a balancing act, with the 
amount of available gold ions within the system being a key factor in influencing particle 
size, however as with all AuNP synthesis methods, factors such as pH, temperature, seed 
concentration and size, stabiliser strength and concentration, and the choice of the solvent 
contribute to the overall size and morphology of the resultant AuNPs [112]. 
Although size control of spherical AuNPs dominates the literature, size control of shapes 
other than spheres has been explored, though to a lesser extent. The size modification of rods 
or more specifically the tuning of their aspect ratio is reasonably well researched. When Yu et 
al. published the electrochemical method for synthesising nanorods (AuNRs) in 1997 [120], 
it not only uncovered the link between aspect ratio and the distinct dual band SPR peaks 
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observed for AuNRs (a concept explored in more detail in section 2.1.2), but went further to 
demonstrate that the second peak (the longitudinal band) could be tuned by modifying the 
aspect ratio of the rods. The exact method by which the group accomplished this was not 
detailed, except to say that it was achieved by “carefully manipulating the experimental 
parameters”. However, in 2009, Wang and co-workers utilised the same method and provided 
details on how rods with differing aspect ratios could be obtained [121]. They noted that rod 
length was controlled by altering the ratio between the surfactant (CTAB) and co-surfactant 
(TOAB or tetradecylammonium bromide). While they achieved some degree of size control, 
and were able to produce short rods with aspect ratios of 3-7, long rods which had aspect 
ratios of 20-35 occurred less frequently. The original work by Yu was also built upon by 
Mohamed et al. in 1998, who additionally noted that increasing the temperature of the 
reaction reduced the aspect ratio of the rods [122].  
Much like spherical AuNPs, rod shaped AuNPs can also be produced using a seed mediated 
approach, with multiple publications on the subject by Murphy Group [123, 124]. The group 
found that the size of shorter rods with aspect ratios under 7 could be controlled by changing 
the ratio of gold seeds to gold salt in the growth solution, with increased aspect ratio rods 
forming with decreasing amount of gold seeds. There was a limit to this effect however, with 
the aspect ratio failing to increase above ~7-10. They did however note lengthening of the 
rods with the addition of a small amount of silver nitrate into the solution [124]. They 
expanded on this work in their next publication; producing higher aspect ratio rods in an 
alternate fashion, by varying the experimental conditions of the seed mediated process. They 
noted that altering the timing of the reaction could increase the aspect ratio from ~13 to ~18. 
The same seed and three identical growth solutions were utilised in both reactions, beginning 
with the addition of the seed to the first growth solution, from which an aliquot was 
sequentially added to the next growth solution in turn. For the ~13 aspect ratio rods the 
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reactions were allowed to run to completion in each growth solution, with aliquots taken after 
4-5 hours. In contrast, the ~18 aspect ratio rods were formed by transferring the growth 
solutions while the particles were still growing, after just 15-30 seconds in each solution 
[125]. Similar to spherical particles, the factors influencing the aspect ratio of AuNRs are 
varied and include: the length of surfactant chain [126]; the size, surface charge and capping 
agent of the seed [127, 128]; and the amount of silver nitrate [79] . 
While there are relatively large bodies of work relating to the size tuning of rod and spherical 
AuNPs, other shapes such as prisms and cubes are less explored. There exists a small body of 
work on controlling the edge length of gold nanoprisms, however unlike silver nanoprisms 
which show a great ability to be tuned [129-131], the dimensions of gold nanoprisms are 
more difficult to control. Ha and co-workers demonstrated some ability to tune the edge 
length of gold nanoprisms by adjusting the pH within the narrow range of ~2.2-3.5. They 
observed increasing edge length with increased pH, however pH levels above 4 failed to 
induce prism formation entirely [132]. 
The majority of size control methods for gold nanoprisms use biological agents such as Aloe 
vera and lemongrass leaf extracts which were utilised by Chandran et al. [133] and Shankar 
et al. [82, 134], respectively in Sastry’s Group. Both these studies observed that increasing 
the amount of leaf extract decreased the edge lengths in the prisms formed. Sastry Group 
further expanded on this research by demonstrating that increased temperatures also led to the 
formation of prisms with shorter edge lengths [135]. 
Millstone and co-workers have conducted a large body of work on the synthesis of both gold 
and silver nanoprisms [7, 130, 136-138]. The group achieved shape control by using a seed 
mediated approach, effectively using freshly synthesised nanoprisms as seeds for further 
growth of larger prisms (Fig. 5). By adding the prisms to a growth solution containing 
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additional gold ions in the presence of excess ascorbic acid they produced nanoprisms with 
edge lengths varying from 100-300 nm [136]. 
 
Fig. 5. Schematic representation of the two growth mechanisms likely to occur in seed 
mediated prismatic particle synthesis. Reprinted with permission from [136]. Copyright 2006 
John Wiley & Sons. 
While significant gains have been made in the area of size control of AuNPs, the resounding 
message in this field is that the process is influenced by many external factors. Due to the 
effect of size on the location and strength of corresponding SPR bands, the desire for shape 
control is sought by many researchers for applications of AuNPs which depend on their 
optical properties. Thus research in this area is expected to expand, with the goals of more 
precise tunability of common shapes and the possibility of controlling additional shapes. 
2.2 Shape controlled synthesis of gold nanoparticles 
In general terms, being able to control and finely adjust parameters for the synthesis of 
AuNPs can benefit many potential applications. While there is limited ability to tune the 
optical properties of AuNPs by altering their size, there is enormous scope for the 
improvement in the range of possible SPR band positions by altering nanoparticle shape. Rod 
shaped AuNPs are arguably one of the most interesting in terms of their SPR potential as they 
exhibit two plasmon resonance bands, one of which can be easy tuned depending on the 
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aspect ratio of the rod [120, 139, 140]. Similar to spherical AuNPs, rod shaped AuNPs 
display an absorption band at around 520 nm due to transverse oscillations or surface 
plasmons oscillating along the short edge of the rod; however a strong longitudinal plasmon 
band, whose position is dependent on the length of the rod, is also present due to surface 
plasmons oscillating along the long edge of the rod. The position of the longitudinal band is 
generally seen at wavelengths at and above 750 nm in the near infrared region of the 
spectrum (Fig. 6), which coincides with the optical transparency window of many biological 
tissues [139, 141]. The optical window describes the wavelength range over which light is 
minimally scattered and absorbed by biological tissue. This means that light can penetrate 
deeper into the skin, without disturbing the tissue and hence allows for imaging of live 
subjects [142]. 
  
Fig. 6. UV-visible absorbance spectra (left) and TEM images of spherical (right, inset) and 
rod shaped AuNPs (right, main panel). Spherical AuNPs show a single absorbance peak at 
~520 nm while rod-shaped AuNPs show a small transverse peak in this region and significant 
longitudinal band at ~900 nm. Unpublished results from the authors’ own work.  
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By including a capping agent in the nanoparticle synthesis process, greater control over size 
and shape can be attained. While the capping agents used to date include polymers, 
dendrimers, additive ionic species [143] and even microbial proteins and metabolites [70], the 
use of a surfactant is the most common way to achieve shape control for metal nanoparticles 
[144]. This is achieved by preferential binding of shape-directing chemical species to 
different facets of a growing gold crystal based on the energy state of the facets, as well as 
steric interactions which relate to atomic density. [126]  
While there are many surfactants which share similar traits, the most commonly used in 
AuNPs shape control is cetyltrimethylammonium bromide (CTAB) [145], which contains 
both a polar hydrophilic head group, and a non-polar hydrophobic tail (Fig. 7). This 
amphiphilic nature predisposes CTAB to form micellar arrangements in solution above a 
certain concentration (called the critical micelle concentration (CMC)), conferring soft-
template like nature. A frequent constituent in topical antiseptics, its cationic head group is an 
effective antibacterial and antifungal agent which targets the outermost membrane of Gram 
negative bacteria [146]. This property, in combination with its surfactant nature justifies its 
inclusion in some cosmetics and personal care products [147, 148]. 
 
Fig. 7. Structure of CTAB. 
While Murphy and co-workers [123] are credited with publishing the wet chemical method 
for gold nanorod synthesis using CTAB, Yu et. al. had previously suggested that the 
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formation of nanorods via electrochemical synthesis was due to the cylindrical-shaped co-
surfactant CTAB [120]. While its mechanism of action is still not definitively known, it was 
clear to early groups that CTAB acted as a soft template [78, 79, 149], which directed growth 
of nanorods by binding preferentially to certain facets of the growing gold crystal. CTAB is 
known to form a bilayer on AuNPs in solution as the surfactant molecules interdigitate, 
arranging their polar head groups both inward to the nanoparticle surface and outward to the 
interface with solution, assisting in stabilisation by preventing agglomeration [128, 150, 151]. 
The exploration of CTAB’s mechanism of action has led to several attempts to explain its 
behaviour during nanorod synthesis [77-79, 145, 152, 153]. In the years following Murphy’s 
publication in 2001, many groups stated that the yield of nanorods obtained by following this 
method was strikingly low (~4%) [154]. This led to several groups adapting the method or 
formulating new methods for synthesising gold nanorods in high yield [78, 79, 139, 155]. 
While groups including Murphy and co-workers [154, 155] published an improvised method 
in which they identified pH as a critical factor for rod formation within their system, methods 
also emerged using micromolar concentrations of silver nitrate (AgNO3) to induce gold 
nanorod formation [78, 156]. Despite the similarity between methods, the addition of AgNO3 
causes the reaction to proceed via a different proposed mechanism, and results in a slightly 
different shaped rod (Fig. 8) as compared with a silver free system [78, 149, 157]. The 
advantage of using silver is a markedly higher yield (~90-100% yield of nanorods is possible 
in a silver containing system compared with ~20-40% in a silver free system [128]), however 
the aspect ratio of rods produced with silver was limited to ~6 (compared with up to ~25 for a 
silver free system) [128, 149]. 
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Fig. 8: Images modelling the crystallographic differences that arise if gold nanorods are 
synthesised using (a) citrate-capped seeds without silver or (b) CTAB-capped seeds in the 
presence of silver. Reprinted with permission from [156]. Copyright 2006 American 
Chemical Society. 
The initial method for rod synthesis devised by Murphy et al., utilises citrate capped 3.5 nm 
gold seed particles, which act in dual capacities as both the initial site of growth and as a 
catalyst to induce reduction [123]. The citrate seed particles develop facets as they grow, 
resulting in the formation of penta-twinned AuNPs [149]. The penta-twinned seed particles 
are structured such that five {111} crystallographic faces are cyclically arranged on each end, 
separated by five side faces which can either be {100} or {110} [77]. Sterically, CTAB is 
accommodated with greater ease on the {100} or {110} faces, when compared with the 
closely packed {111} face, and hence, a bilayer of CTAB forms along these faces, blocking 
growth, while leaving the end face exposed for further growth [149]. CTAB helps to control 
the rate of the reaction by limiting the interaction of gold ions, and adding the weak reducing 
agent ascorbic acid to the rods allows growth to occur more quickly at the tips of the rods, 
which results in elongation [156]. 
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In contrast, CTAB capped seeds were also employed to synthesise gold nanorods in the 
presence of silver [78]. These 1.5 nm seed particles are single crystalline and appear to have 
four {100} side faces, and two {100} faces on the ends. The exact mechanism of action of 
silver is not known, however it is thought to significantly slow the reaction process, and also 
act as a template via silver underpotential deposition (UPD) [78, 152, 158]. Silver UPD 
occurs when silver becomes reduced at a metal surface which holds a surface potential that is 
lower than the expected reduction potential of silver. This is energetically favoured on the 
{110} surface [159], which leads to faster reduction of Ag+ to Ag0 compared to the {100} 
face. It is thought that the presence of silver allows CTAB to bind more effectively to the 
{110} surface, and this synergistic effect promotes lengthening of the rods [156]. 
While CTAB is most commonly associated with gold nanorod formation, it can also be used 
to encourage cubic AuNP formation [157, 160-162]. Gold seed particles which are intended 
for cubic shaped particle growth such as those used by Kim et al., are typically stable, with 
{111} faces accessible [163]. When in the presence of CTAB, which preferentially binds to 
the {100} face over the {111} face, the {100} faces are effectively “blocked”, and growth is 
encouraged on the {111} face, forming cubes [161]. For this to occur, the synthesis requires 
elevated levels of a weak reducing agent such as ascorbic acid to be included in the system. 
Although incapable of facilitating a complete reduction of Au3+ ions, it ensures partial 
reduction to Au+ ions. The final step, a careful addition of sodium hydroxide into the reaction 
vessel, is done with no mixing, as immediately mixing the solution causes an influx in fully 
reduced Au0 atoms, hastening uncontrolled growth in various directions leading to octahedral 
growth. Delaying mixing for more than 6 hours allows a very slow formation of Au0 atoms, 
allowing CTAB to prevent undirected growth, forming cubes [157].  
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While there are many published methods for producing gold nanorods using CTAB, it has 
emerged more recently that a number of research groups found this work difficult to 
reproduce. The most common issue found was that despite closely following the published 
synthesis protocols, the result yielded only spheres, with no or negligible rods formed within 
the growth solution. The first report of this was in 2007 when Durr and co-workers found that 
the use of high-purity (>99%) CTAB did not result in rod formation, however a less pure 
(96%) CTAB produced rods in high yield [47]. Though the group’s focus was to utilise gold 
nanorods for medical imaging, they pursued this oddity further, testing five CTAB products 
from different suppliers, with purities ranging from 96-100%. When the products of lower 
purity returned favourable results, the group concluded that an unknown impurity was most 
probably responsible for this effect [47]. Members of the same group, Smith and Korgel 
pursued this further the following year, testing ten CTAB products under identical conditions 
for rod formation [153]. Of these samples, three failed to yield rods, sustaining their earlier 
reports that the impurity in the CTAB was critical for nanorod formation [47, 153]. While it 
was not definitive whether the impurity induced or prevented nanorod formation, it was 
hypothesised that the impurity disrupted nanorod formation during the growth phase. That 
same year, Millstone and co-workers detected levels of iodide (I-) on the surface of gold 
nanoprisms via inductively coupled plasma mass spectroscopy (ICP-MS) and confirmed with 
XPS (Fig. 9), which was surprising as it was not intentionally added during the synthesis and 
had no obvious origin. By performing ICP-MS on the starting constituents of the synthesis, it 
was determined that iodide was present in the CTAB which possibly accounted for the 
published inability to synthesis rods. This agreed with later reports by Smith’s group and 
Rayavarapu and co-workers, and furthermore most of the researchers active in AuNP 
synthesis agreed that it was possible to have batch to batch variation of iodide content despite 
using products from the same supplier with a common product number [153, 164]. The 
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mechanism responsible for the iodide interference was attributed to its strong affinity for the 
{111} crystal surface [165]. In ideal conditions for rod formation, the {111} surface must be 
left unblocked (or at the very least partially unblocked) to allow for lengthening of the rods to 
occur. However when a growth system includes sufficient levels of both iodide and CTAB, 
binding to the {111} and {100} or {110} surfaces respectively, rods formation becomes 
improbable, with spheres being the most likely outcome.  
 
Fig. 9. (A) XPS spectra of gold nanoprisms synthesised by Millstone et al. Presence of I- is 
evident, and (B) not detected in spherical and rod shaped particles synthesised. Reprinted 
with permission from [138]. Copyright 2008 American Chemical Society. 
While this property makes iodide ions highly undesirable for inclusion in gold nanorod 
synthesis, it is the key to forming triangular gold nanoprisms [135, 138, 166]. As with all 
crystals, each plane possesses a distinct energy level which is dictated by the reactivity of its 
surface electrons. For gold, a face centered cubic (fcc) metal, the order of its crystallographic 
planar energy is s(111) < s(110) < s (100) [165]. While it is known that iodide preferentially 
adsorbs to the lowest energy facet of a growing nanoparticle crystal, if concentrated 
sufficiently, it binds to all surfaces of the crystal [7]. When this occurs, growth is thought to 
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favour the higher energy facets, (110) and (100), which results in lengthening of the prism 
edges, rather than increasing the prism thickness [130]. It is postulated that this growth effect 
may also have stoichiometric justification, as it requires fewer gold atoms to lengthen an 
edge, as compared to increasing the overall thickness of the particle [130]. Some examples of 
the various shaped CTAB synthesised AuNPs discussed are shown in Fig. 10. 
 
Fig. 10. TEM images (clockwise from top left) of rod shaped, cubic, quasi-spherical and 
prismatic AuNPs synthesised using CTAB as a shape directing surfactant. Unpublished 
results from the authors’ own work. 
2.3 Effect of reducing agents and stabilisers on the synthesis of gold nanoparticles  
With the Turkevich method of spherical AuNP synthesis so widely used, the effect of citrate 
present on the resulting AuNP surface has been noted by many groups. The negative charge 
of the citrate coating influences the interactions of the particles with other species and can 
limit researchers in terms of further surface functionalisation. Notably, the negative charge 
inherent to DNA hampers its electrostatic binding to citrate stabilised particles, although does 
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not preclude it fully [167]. Similarly, bovine serum albumin (BSA) binding to citrate 
stabilised AuNPs is approximately two times less than that of bare gold [168], thus 
emphasising the idea that individual components chosen during nanoparticle synthesis can 
influence the surface chemistry of the final particles. For this reason surface modifications 
and the development of new methods of AuNP synthesis became necessary for biological 
applications, to create particles with controllable surface chemistry, surface charge and 
stability. There are many comprehensive reviews that cover the synthesis of AuNPs in great 
detail [70, 103, 105, 128, 169-171]. In the current article, we highlight some of the key 
chemical agents used in nanoparticle synthesis which relate to the uptake and toxicity 
discussions covered in Sections 3 and 4 of this review. 
Various chemicals can be used as reducing agents during AuNP synthesis, the most common 
being sodium borohydride, sodium citrate, ascorbic acid, and amino acids [14, 124, 149, 
172]. The strength of the reducing agent (or the ease with which it is oxidised) plays an 
important role in controlling the rate of the reaction, thereby influencing the morphology of 
obtained AuNPs [135]. For instance, sodium citrate is a relatively weak reducing agent, and 
thus the reduction reaction does not occur instantaneously, but over approximately 10 
minutes [70]. It is of no surprise that when citrate salts are employed as reducing agents, the 
AuNP synthesis is performed under boiling conditions to enhance the reaction rate, thus the 
modified Turkevich method devised by Frens reduces the amount of sodium citrate in order 
to achieve larger particles [72], a concept discussed in further details in Section 2.1.1. 
Further, while reducing agents tend to stabilize AuNPs during synthesis, sometimes 
stabilisers are also used to achieve additional control over AuNPs, such as, halting further 
growth and preventing aggregation of the particles over time. As with reducing agents, a 
number of stabilisers can be used during AuNP synthesis such as sodium citrate, polyethylene 
glycol (PEG), tetraoctylammonium bromide (TOAB) and cetyltrimethylammonium bromide 
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(CTAB) [70], as well as greener alternatives such as leaf [97, 173], seed [95, 96] and fruit 
extracts [174]. Typically, strong reducing agents such as TOAB and sodium borohydride only 
bind weakly to the surface of AuNPs during synthesis, such that over time, stored AuNP 
solutions stabilised with these agents tend to agglomerate. In such cases, the use of additional 
stabilisers provide an opportunity to prepare monodisperse yet stable AuNPs [175]. 
Stabilisers can also play an important role in controlling the morphology of AuNPs (explored 
in greater detail in Section 2.1.2) through binding preferentially to specific planes of a 
growing Au nanocrystal, and thereby blocking the further growth of that specific plane [176, 
177].  
In summary, methods for synthesizing AuNPs have grown exponentially since their 
discovery by Faraday over 150 years ago. We are now capable of synthesising different 
shaped AuNPs to suit a plethora of applications which differ from imaging [11, 47, 55, 139, 
178-184], to therapeutics [12, 53, 98, 142, 179, 184-193] and sensing [194-197]. These 
AuNPs can be tuned with varying degrees of size control, despite researchers not necessarily 
understanding the full mechanisms which underpin the process. It is only through continued 
work and documentation in this field that we will understand the intricacies through which 
these synthesis reactions proceed. 
3. Toxicity of nanoparticles 
As a global multi-billion dollar industry, the area of engineered nanomaterials (ENMs) is 
rapidly growing, with an expanding list of applications [198-205]. While these applications 
are diverse in terms of their end use, they form the basis for growing environmental, health 
and safety concerns. Despite many applications of nanotechnology not being intended for 
medical or biological applications, there remains a necessity to investigate all new 
nanomaterials in terms of risks related to the manufacturing and use of the materials as well 
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as the environmental ramifications of their use and disposal [57, 206]. The innate size of a 
nanoparticle means that cellular interactions are highly likely (Fig. 11). Nanoparticles 
comparable to the size of a virion or bacterium are small enough to penetrate the cellular 
membrane and accumulate within the cell [207, 208].  
 
Fig 11: Schematic of the human body depicting likely routes of nanoparticle internalisation, 
and likely health effects from nanoparticle interaction. Reprinted with permission from [207]. 
Copyright 2007, American Vacuum Society. 
In reality, humans have been exposed to nano- and micron-sized materials for thousands of 
years. Early exposure did not originate from the laboratory, but from nature, dictated by such 
events as dust storms, eruptions of volcanic ash, and the evaporation of oceans which 
generates nanoparticulate salt aerosols [207]. Since the nineteenth century, human exposure 
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to nanoparticles has increased markedly, with the proliferation of combustion engines and an 
increase in cigarette sales among other causes [207, 209, 210]. The likelihood of exposure to 
intentionally designed nanomaterials is relatively small for most of the population in 
comparison to exposure from other anthropogenic and naturally occurring sources; however 
due to their common size, the investigation of their health effects unites under the umbrella of 
nanotoxicology [57, 211].  
Although nanoparticles can theoretically be created from any element, the vast majority of 
research is performed on nanomaterials derived from carbon, silicon, polymers, metals and 
metal oxides [199]. Each of these materials in their bulk form possesses vastly different 
characteristics which may or may not be inherited by their nanoparticle counterparts [13]. 
While we know that size is an important factor for defining a nanomaterial, when examining 
the interaction between a biological interface and an ENM, there are over 30 variable factors 
which are known to have an impact on the way that nanoparticles are recognised, up-taken 
and processed intracellularly [211]. These variables include, but are not limited to size, shape, 
surface charge, surface area, surface functionality, suspending media, tendency for 
aggregation, chemical nature and the nature of its protein corona in biological fluids [212]. 
Hence the merits and dangers of individual ENMs must be assessed on a case by case basis, 
until enough is understood about ENMs to predict the properties and behaviours of new 
samples [213]. 
3.1. How to assess the toxicity of nanoparticles? 
While it may be possible to predict biocompatible or bio-adverse results based on surface 
chemistry in silico, measuring the toxicity of nanoparticles in cellular systems in vitro is a 
necessary prerequisite for medical or consumer use of ENMs [57]. There are myriad of 
established assays for assessing the toxicity of materials in cellular systems which can be 
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grouped into general categories depending on the endpoint measured [214]. The question 
posed by many research groups [206, 211, 215-218] is whether assays which have been 
optimised for general chemical compounds can be used to measure the effects of ENMs or 
whether the assays require modification to assess nanoscale materials. 
Permeability assays, which assess viability based on the integrity of the cellular membrane 
most commonly include dye inclusion/exclusion assays (e.g., trypan blue which selectively 
stains dead cells but cannot permeate the membrane of living cells) and cytolysis detection 
assays which measure specific intracellular substances (e.g. lactate dehydrogenase (LDH) 
which is released from lysed cells when they die) [57]. A general disadvantage to the use of 
permeability assays is related to the endpoint itself [214]. By measuring toxicity only at the 
point where the cell membrane ruptures, it would be incorrect to assume that the cells deemed 
viable are in fact fully functioning, healthy cells. In reality, permeability assays cannot detect 
early or more subtle forms of cellular stress or damage. While this fact remains true for 
trypan blue, there are no noted specific disadvantages related to the use of ENMs in this assay 
[218]. It should be noted however that it can become time consuming and cumbersome to 
perform the trypan blue assay on a large number of samples when compared with other 
techniques. On the other hand, interference was noted by Han and co-workers between LDH 
assays and copper, silver and titanium dioxide nanoparticles [215]. This interference is due to 
adsorption of the LDH molecule onto the nanoparticles, which causes a decrease of free LDH 
within the system, which manifests as falsely reduced toxicity measurements.  
Functional assays are often utilised as they relate to a specific metabolic pathway or function 
performed by the cell to a quantifiable level of cell viability. Common examples of this form 
of assay include tetrazolium-based assays such as MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] and MTT [3-(4,5-
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dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] [219], as well as alternatives such as 
the Presto Blue metabolic assay [181], and Neutral Red assays [220]. Tetrazolium salts are 
able to selectively identify metabolically active cells because only these cells possess the 
mitochondrial activity required to cleave a tetrazolium ring thus creating formazan. Formazan 
formation results in a visible purple colour (Fig. 12), which appears only in viable cells, 
giving rise to the ability to detect the amount of viable cells colorimetrically [219]. While this 
type of assay is very commonly used, they may not always be suitable for assessing ENMs. 
Carbon nanotubes (CNTs) cannot be reliably tested using this assay because they adsorb 
formazan which falsely appears as decreased colour formation and can be interpreted as 
decreased cell viability [217, 219]. This may be avoided by the addition of a step to remove 
the nanoparticles from the cell containing plate before adding the tetrazolium compound; 
however this is not traditionally commonplace [206]. As a precautionary measure, particles 
can be tested in a cell free system to check if they have any formazan reduction activity prior 
to performing the full assay. Such a test was carried out by Sayes et al. on zinc oxide 
nanoparticles to establish that they had no effect on formazan reduction [221]. Considering 
that a number of ENMs which utilize AuNPs possess wide ranging catalytic [222] and 
nanozyme properties [194, 195], it is likely that many ENMs may not be suitable for testing 
in all cytotoxicity assays. Unfortunately, most published reports on cytotoxicity of AuNPs 
and other ENMs fail to undertake such precautionary tests, resulting in a vast amount of 
literature citing outcomes which may not be fully trusted without revalidation. 
Another common problem encountered with assays which are read spectrophotometrically 
such as MTS and MTT is that each nanoparticle absorbs light over a particular wavelength 
band, which may coincide with the wavelength that the assay is read at. This has been 
reported to be the case for sodium titanate nanoparticles [223] as well as citrate stabilised 
AuNPs [218]; however this problem may be potentially alleviated by adding a centrifugation 
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step to the MTT protocol or by removing the nanoparticles prior to the addition of the 
tetrazolium compound [218]. Despite this fact, it is not common practice in such assays to 
remove the analyte before continuing the assay. Moreover, the innately “sticky” nature of 
ENMs, (adhering to the reaction vessel, cellular surface, etc.) makes it difficult for the EMS 
to be removed without disturbing the surrounding cells before performing assays. Alternate 
strategies, such as those involving control experiments, wherein pre-fixed (dead) cells are 
exposed to ENMs to assess non-specific cellular binding of ENMs, may address the issue or 
ENM’s stickiness to the cellular surfaces. 
 
Fig. 12. A 96 well plate after development of purple formazan crystals, denoting cell 
viability. 
Genomic or proteomic assays such the enzyme-linked immunosorbent assay (ELISA) are not 
impervious to similar forms of interference [206]. ELISA can be used to determine if 
proinflammatory markers or cytokines, such as TNFα [56], interleukin 1-β [56], interleukin-6 
or interleukin-8 are being released from cells following treatment with nanoparticles. For 
instance, CNTs were found to adsorb interleukin-8 as reported by Montiero-Riviere and 
Inman [224], while Veranth and co-workers [225] reported other nanoparticles including 
SiO2 and TiO2 behaving similarly in the case of interleukin-6, leading to the detection of 
lower than expected levels of cytokines. 
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The resounding message emerging from the literature regarding the toxicity of nanomaterials 
highlights the importance of choosing an appropriate assay for each individual ENM with 
consideration for the endpoint being examined, and to perform appropriate control 
experiments before critically analysing the results obtained. It is obvious that each assay must 
be optimised for new nanomaterials, adding additional steps to minimise interference when 
necessary. Where possible it is also advised to cross check results by using more than one 
assay to expose false readings [217]. From the authors’ experience, some of the foremost 
considerations that must be followed in choosing the correct assays for toxicity assessment of 
ENMs including gold, are: (i) appropriate assessment of the potential for nanoparticle 
aggregation in cell culture medium, (ii) careful assessment of potential adsorption of the 
assayed component onto the nanoparticle surface, and (iii) consideration of the nanoparticle’s 
inherent chemical activity in producing the reaction product. For instance, it is now well-
established that gold and many other metal nanoparticles show strong reducing capabilities. 
Since MTS/MTT assays rely on reduction of these tetrazolium compounds into formazan 
crystals, one must be very cautious when choosing such assays for assessing biocompatibility 
of metal nanoparticles. Similarly, recent reports have demonstrated that some of the 
nanoparticles such as gold and iron oxide behave as nanozymes by demonstrating biological 
enzyme-like activity (peroxidase, catalase, etc.) [194, 195]. These new findings may further 
influence the way ENMs should be assessed for in vitro cytotoxicity. 
Of equal importance in choosing the correct assay to assess the toxicity of ENMs is 
identifying an appropriate line of cells on which to perform the assay. It is commonly thought 
that incidental exposure to nanoparticles is via respiration, ingestion or through the skin [211, 
213, 216]. For this reason, nanoparticle toxicity assays are commonly performed on skin cells 
or cells from the respiratory or gastrointestinal systems [60, 62, 224-226]. However 
researchers interested in assessing the therapeutic potential of ENMs in applications such as 
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biological imaging [54, 183, 227, 228] and drug delivery [227, 229-234] perform tests on 
common tumour cell lines of the breast [144, 178], prostate [178, 185, 235] and cervix [59, 
236]. While it appears appropriate to choose cell lines depending on the end application, to 
assess the overall cytotoxicity of a particular ENM, it is critical to test a number of different 
cell lines in a single comprehensive study. 
Assay Principle Common Issues Reference 
Trypan blue 
assay 
Exclusion test - 
selectively stains dead 
cells. 
Time consuming for 
multiple samples. 
[237] 
LDH assay Cytolysis detection 
assay.  
Measures release of 
LDH colorimetrically. 
Time consuming for 
multiple samples. 
LDH adsorption by 
ENMs (including Ag, Cu 
and TiO2). 
Inhibition of LDH 
activity. 
ZnO [238, 239] 
Cu and TiO2[215] 
Ag [215, 240] 
Neutral Red 
Assay 
Functional Assay. 
Measurement of viable 
cells after lysosomal 
uptake of dye. 
Dye adsorption by ENMs 
(e.g. Carbon). 
Optical interference. 
Carbon ENMs [219, 
224, 241] 
Fe3O4 or TiO2[242] 
Tetrazolium-
based assays 
(MTS and 
MTT) 
Functional Assay. 
Tetrazolium conversion 
to formazan, allows 
measurement of 
metabolically active 
cells colorimetrically. 
Formazan adsorption by 
ENMs (including CNTs). 
Susceptible to reduction 
by other species (i.e. 
superoxide). 
Optical interference. 
CNT [241, 243, 
244] 
Carbon ENMs [224, 
238] 
TiO2[238, 245] 
Si [246] 
Ag [247] 
Metal oxides [248] 
Au[218] 
Enzyme-linked 
immunosorbent 
assay (ELISA) 
Analytic assay for the 
detection of immune 
response. 
Measurement of the 
release of cytokines 
colorimetrically. 
Adsorption of cytokines 
by ENMs (e.g. CNTs and 
interleukin-8). 
TiO2 [225] 
SiO2 [225] Carbon 
ENMs [224, 249, 
250] 
Fe3O4 [242] 
Comet  assay Single-cell gel 
electrophoresis.  
Detects DNA damage 
by measuring single- 
and double-strand 
breaks in DNA. 
Interference with 
formamidopyrimidine 
DNA glycosylase. 
Direct DNA-ENM 
interaction 
Photocatalytic ENMs, 
can generate increased 
DNA damage after 
exposure to UV light 
Ag, CeO2, 
Co3O4 and SiO2 
[251] 
TiO2 [252] 
CeO2, TiO2, SiO2 
[253] 
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(e.g. TiO2) 
Micronuclei 
test 
Identification of 
cytogenetic material by 
measuring changes in 
the frequency of 
micronucleus 
formation. 
Decreased NP 
endocytosis after 
treatment with 
cytochalasin B. 
Fe3O4[254] 
Table 1. Summary of commonly used assays for the cytotoxicity assessment of nanomaterials 
and the likely points of interference associated with each assay. 
3.2. Uptake and toxicity of gold nanoparticles  
To date, the techniques used to measure of the toxicity of AuNPs of varying shapes and sizes 
are consistent with the techniques used for nanomaterials in general (as outlined in Section 
3.1). For AuNPs, a range of techniques have been employed including LDH [255] and trypan 
blue [256], however the "gold standard" assay [64, 65] for cytotoxicity is the MTT assay 
which is by far the most commonly used [56, 257-262]. While there are a small number of 
reports of inference to the MTT assay by AuNPs [218, 263], there are multiple ways in which 
the MTT assay can be modified to overcome specific issues [206].  
While gold in its bulk form, and particles of micron size range or larger, are generally thought 
of as non-catalytic, stable, inert and biocompatible, the uptake and toxicity of AuNPs is a far 
more complex issue [65]. With key variables such as the synthesis, size and shape of the 
nanoparticle as well as the cell type and endpoint examined [264], researchers have begun to 
form a matrix of results based on these findings. While some studies draw valid comparisons 
based on their own results [59], other reviews collate and compare the toxicity of particles 
synthesised by different groups over many years, using varied synthesis methods [64, 65, 
265]. 
Shukla et al., published one of the pioneering reports on biocompatibility assessment of 
AuNPs [56]. This study examined the cytotoxicity and intracellular uptake dynamics of 
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AuNPs in macrophage cells. Atomic force microscopy (AFM) studies shed light on 
endocytosis processes involved in AuNPs uptake, while revealing that AuNPs taken-up by 
the cells could not be expelled out of the cells for extended time periods. One of the notable 
findings of this study was that these AuNPs were not only found to be highly biocompatible, 
they showed antioxidant properties at higher dosages and longer treatment points. This was 
concluded based on their ability to reduce the level of reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) produced by the cells. This study also demonstrated for the 
first time that spherical AuNPs didn’t induce the formation of proinflammatory cytokines 
such as TNFα and interleukin1β by macrophage cells. 
This study was followed by a comprehensive study by Chithrani and co-workers with regards 
to nanoparticle shape, size and toxicity [59]. The study examined five citrate stabilised 
spheres of different diameters and two CTAB stabilised rod-shaped AuNPs of different 
aspect ratio. To be able to compare the particles in terms of toxicity and uptake, the positively 
charged CTAB present on the surface of the gold nanorods was exchanged with negatively 
charged citric acid ligands so that it was common across all seven nanoparticles. The study 
concluded that nanoparticles synthesised in this way did not cause toxicity to HeLa (immortal 
cervical cancer) cells in the doses examined. This finding of negligible toxicity has been 
validated by ours and many other groups who tested spherical [56, 236, 257, 262, 266] and 
rod shaped [260] AuNPs in a number of different cells. 
In contrast to these reports, some other groups such as Patra and co-workers synthesised one 
particular type of nanoparticle, e.g. citrate-reduced 33 nm spheres and tested its toxicity in 
three different cell lines [267]. Their results showed that the same nanoparticle was toxic in 
human carcinoma lung cells (A549), while remaining nontoxic over the same dose range in 
both baby hamster kidney cells (BHK21) and human hepatocellular liver carcinoma cells 
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(HepG2). When better understood, this cell-selective effect could be harnessed as a possible 
treatment for certain forms of cancer. 
In 2010, Alkilany and Murphy compiled a comprehensive review of other group’s results 
regarding the toxicity and cellular uptake of AuNPs [64]. Over 20 studies were examined, 
most commonly, groups studied spherical and rod shaped particles, however a range of 
chemical stabilisers were employed including citrate (most common), CTAB, various amino 
acids, and PEG both in vitro and in vivo. The authors found that there was no clear 
conclusion to draw on the toxicity of AuNPs, with such conflicting results between groups. 
The analysis of existing research outcomes led them to hypothesize that particle uptake, 
distribution and toxicity depended greatly on the interaction between the particle surface and 
the surrounding biological media [64, 265].  
3.2.1. Effect of gold nanoparticle size on uptake and toxicity  
Using methods such as ICP-MS and related techniques, it is possible to quantify the uptake of 
nanoparticles by relating the gold concentration of a known population of AuNP treated cells 
to the number of particles per cell. These results can be confirmed visually using electron 
microscopy. Chithrani and co-workers performed such a study on 14, 30, 50, 74 and 100 nm 
gold spheres [59]. The study estimated the number of nanoparticles per cell (calculated from 
the number of gold atoms obtained using inductively coupled plasma atomic emission 
spectroscopy), and found that maximum uptake (by number) occurred for the 50 nm particles; 
however despite the difference in uptake quantity, none of the spherical particles tested 
induced any significant cytotoxic event. These findings correlate well with other groups who 
found similar size dependent trends for uptake maxima [268-270] as well as uptake speed 
maxima [271] for ~50 nm AuNPs. The studies that performed additional electron microscopy 
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found that 50 nm AuNPs could not enter inside the nucleus, a possible reason for their lack of 
toxicity [59, 271].  
In one of our earliest investigations, using a combination of imaging tools such as TEM, 
AFM and confocal microscopy, we demonstrated that when ~10 nm AuNPs were exposed to 
RAW264.7 macrophage cells, these particles were sequestered in the endosomes, and these 
endosomes migrated from the cellular membrane towards the nucleus in a time-dependant 
fashion [56]. Even after longer exposure times, while endosomes carrying these AuNPs were 
found to beautifully arrange themselves just outside the endoplasmic reticulum network 
emerging from the nuclear pore, none of the AuNPs were observed to penetrate the nucleus 
(Fig. 13).  
 
Fig. 13. TEM image of a RAW264.7 macrophage cell dosed with ~10 nm AuNPs. Triangular-
tipped arrows show the reticuloendothelial network emerging from a nuclear pore. The 
square-tipped arrows show AuNPs present inside lysosomal/ endosomal bodies. Reprinted 
with permission from [56]. Copyright 2005 American Chemical Society. 
One proposed mechanism for seemingly enhanced uptake of AuNPs is that their size is within 
the range of viruses and lipid-carrying proteins which would typically be engulfed or 
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endocytosed by the cell [268]. However, the broader literature is less clear, with reports 
varying depending on surface modifications and the cell line chosen. There are many reports 
which indicate that AuNPs of varying sizes demonstrate negligible toxicity [56, 236, 257, 
262, 266]; however there are also significant number of papers which dispute this [272-274]. 
A notable in vivo example of size dependent toxicity was obtained by Chen and co-workers 
who tested eight AuNPs of sizes ranging from 3 to 100 nm, injecting the doses 
intraperitoneally into mice [274]. While nanoparticles of sizes 3, 5, 50 and 100 nm did not 
induce any apparent cytotoxic effects, AuNPs ranging from 8-37 nm initially caused changes 
in appetite and fur colour, progressing to bruising and bleeding under the skin, the 
development of a crooked spine and eventual death. Physiological changes were detected in 
lung, liver and spleen tissue samples taken from the mice treated with 8-37 nm AuNPs that 
were not seen in mice dosed with smaller or larger nanoparticles. These changes include the 
presence of emphysema like structures within the lungs, depletion of immunologically active 
lymphoid tissue within the spleen and an increase in Kupffer cells inside the liver, which 
would suggest that it was the site of a large scale immune response [274]. 
While typical cell culture experiments are most often based on the methodology of single 
exposure and subsequent reading, the long term effects of exposure to AuNPs hold equal 
importance. By exposing human dermal fibroblasts (CF-31) to citrate-capped 13 and 45 nm 
spherical AuNPs for up to six days, Mironava et. al., determined that despite an initial 
increase in doubling time observed as a function of concentration for both particle sizes, the 
effect on the cells was not permanent [275]. Using electron microscopy, the cells were 
observed to transfer internalised AuNPs to their daughter cells during division, effectively 
decreasing the number of internalised particles in each cell over time. As the number of 
internalised particles decreased over generation, the cell doubling time returned to that 
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similar of the control cells over a 5 day recovery period. These findings are in agreement with 
Liaw and co-workers who tested citrate-capped 10 nm spherical AuNPs on human osteogenic 
sarcoma cells (MG63) [276]. By exposing cells to the nanoparticles for a period of 20 hours 
(at concentrations of 1 and 10 ppm) and monitoring them for a further 21 days they 
concluded that there was no difference in viability, doubling time or morphology compared 
with the control group at the final time point. These observations highlight the significance of 
exposure levels, such that if the organism is able to tolerate the chosen dose initially, it may 
be able to overcome cytotoxicity through in vivo metabolic mechanisms. 
3.2.2. Effect of gold nanoparticle shape on uptake and toxicity 
While there are studies that discuss the synthesis of triangular/prismatic [7, 78, 135, 144, 149, 
277, 278] and cubic [41, 144, 149, 157, 161, 162] AuNPs and their potential for biological 
use, such particles have been the focus of relatively few biological studies in comparison to 
spherical nanoparticles. Following spherical AuNPs, the shape that has captured the highest 
interest of researchers is the gold nanorod, with the relationship between toxicity and nanorod 
length, or more specifically their aspect ratios, explored by many groups [64, 142, 260, 279-
282]. 
As previously discussed, gold nanorods are popularly synthesised using CTAB, a cationic 
surfactant used to influence shape; however pristine CTAB above 1 µM concentration has 
been shown to be toxic to certain mammalian cells [62]. For this reason, some groups choose 
to modify gold nanorods originally synthesised using CTAB, by chemical exchange or 
surface functionalisation to give the particles a new, less toxic coating. Cellular uptake of 
these rods, when compared to spheres, has been shown to be slower, in lower quantities, and 
to induce a higher cytotoxic response [59, 60, 280, 281]. Surface modifications often involve 
the use of polymers such as PEG to dispel the toxicity associated with CTAB; however it is 
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reported that this high molecular weight non-fouling molecule discourages cellular uptake 
[212, 283], and drastically slows the process of endocytosis [60]. When comparing the effect 
of changing the aspect ratio of rods it was found that lower aspect ratio rods are taken up in 
higher quantities than those with higher aspect ratios (Fig. 14) [59]. This is somewhat 
expected as spherical AuNPs, which have the lowest possible aspect ratio (1:1) are generally 
uptaken by cells in much higher quantities. 
 
Fig. 14. Uptake of spherical versus rod AuNPs, showing preferential uptake of spheres (or 
particles of aspect ratio 1:1) Reprinted with permission from [59]. Copyright (2006) 
American Chemical Society. 
Other groups elected to test their gold nanorods as-synthesised, without any modification of 
the surface. Wang and co-workers examined the uptake and toxicity of various sized gold 
nanospheres (synthesised without CTAB) and gold nanorods (synthesised with CTAB) [62]. 
While they found no toxic effect from all tested nanospheres, they found a drastic increase in 
toxicity from all gold nanorods. The group related the increased toxicity to levels of free 
CTAB within the sample, i.e. CTAB left unreacted after synthesis which is not bound to the 
surface of the particles, and performed a more thorough series of wash steps using 
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centrifugation. After washing the particles three times, they observed a 60% improvement in 
cell viability compared with the same particles unwashed. Highlighting the degree of 
improvement that can be gained from washing gold nanorods thoroughly, Connor and co-
workers eliminated toxic effects completely from CTAB AuNPs by centrifugation and 
washing, contrasting with high levels of toxicity for unwashed particles [257]. 
While less explored, preliminary studies have also been performed on the effect of prismatic 
AuNPs on various cells – both human and animal. Singh et al. [284] synthesised gold 
nanoprisms using fresh lemon grass extract, an example of one of the many biogenic 
synthesis methods developed to provide shape control. The difficulties related to making high 
yield nanoprisms (or purifying solutions to retain a high yield of nanoprisms) is well 
documented in the literature [82, 285, 286], and as such, TEM images of the particles used by 
the group depict many persistent small spherical particles, as well as prisms with “edges cut” 
– effectively hexagons. Negating potential issues with sample purity, the nanotriangles were 
found to be well tolerated by cancerous and non-cancerous cell lines, with 80% cell viability 
at doses of up to 800 µM. Further imaging studies confirmed that the cells do take up the 
prismatic particles; however these particles did not enter the nucleus, but rather remained 
within the cytoplasmic space. 
While the effect of shape can be quite drastic when comparing forms such as spheres and 
rods, Wani and Ahmad performed a shape and size dependant study on the antifungal activity 
of two AuNP samples, viz. gold nanodisks and mixed polyhedral shapes [49]. While they 
drew a conclusion that the enhanced antifungal activity observed from the gold nanodisks 
was due to their size, in reality, the two sets of shapes were not clearly defined, with mixed 
populations and high polydispersity apparent. The two shapes were synthesised using 
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different methods, utilising different reducing agents, which also has the potential to 
influence the difference in activity.  
Overall the findings suggest that while there may indeed be shape specific effects on cellular 
uptake and toxicity of AuNPs, the importance of eliminating surface and size effects to draw 
clear conclusions on the effect of gold shape on biological activity remains paramount. 
3.2.3. Effect of gold nanoparticle surface characteristics on uptake and toxicity 
Use of the term “gold nanoparticle” typically refers to a nanoparticle synthesised with a hard 
inorganic gold core and almost always with a soft organic corona. However, depending on 
the method of synthesis, and any modifications applied post-synthesis, the surface may vary 
greatly between different AuNPs [211]. It is widely thought that the chemical composition of 
a nanoparticle is one of many factors which contribute to the level of cytotoxicity it exhibits; 
however there are relatively few studies which explicitly establish this precedent.  
Connor and co-workers demonstrated that starting materials such as gold salt (AuCl4-) and 
CTAB were cytotoxic when tested alone, however when they were utilised along with other 
chemicals during synthesis, the resulting nanoparticle did not necessarily show cytotoxic 
effects [257]. The group tested spherical particles surface modified with cysteine, citrate, 
glucose, biotin and CTAB, finding negligible cytotoxicity in human leukemic cells [257].  
In a similar system, Das et al. looked at three spherical AuNPs with different surface 
modifications – aspartic acid, trisodium citrate dihydrate and BSA finding negligible 
cytotoxicity from all particles through in vitro testing [187]. The group also tested the 
nanoparticles on mice to monitor toxicity after ingestion. In this experiment, the particles 
stabilised with BSA were found to be the most biocompatible, while the particles stabilised 
with aspartic acid and trisodium citrate dehydrate exhibited damage to the liver and kidneys. 
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The group identified stability of nanoparticles in biological media and surface charge as key 
factors in influencing biocompatibility of nanoparticles [187].  
The effect of surface charge has been investigated by many groups [258, 260, 287] to 
determine its role in cytotoxicity. Goodman and co-workers found that identically synthesised 
cationic and anionic spherical AuNPs exhibited different cytotoxicity levels, with cationic 
particles observed as moderately toxic while anionic particles were deemed nontoxic [258]. 
This disagrees with the findings of Schaeublin and co-workers who tested three spherical 
AuNPs; positively charged, negatively charged and neutral [287]. In this study, both the 
positively and negatively charged particles were found toxic, with the negatively charged 
particles eliciting a stronger cytotoxic effect. The authors concede that this may be related to 
the outer chemistry of the cationic particles not being similar, due to different methods of 
charging the particles surface.  
More recently, to understand how nanoparticle surface charge influences their uptake and 
toxicity, our group utilised tyrosine amino acid-reduced/capped AuNPs as a model system 
(Fig. 15) [172]. These negatively charged AuNPs showed no toxicity to Gram negative 
Escherichia coli bacteria and A549 human lung carcinoma. When the negative charge on the 
AuNPs surface was reduced through coating with a cationic amino acid lysine, it was noted 
that although nanoparticle uptake increased for both the bacteria and mammalian cells, it did 
not influence their toxicity. These observations were further validated by functionalising 
tyrosine-capped AuNPs independently either, with a cytotoxic polyoxometalate molecule or 
with polyoxometalate in combination with lysine. This investigation showed that the 
cytotoxicity of these polyoxometalate-functionalised AuNPs is dependent on the overall 
surface charge of the AuNP carrier system such that with an overall reduction in negative 
charge, the uptake and therefore cytotoxicity is enhanced. In contrast, when we utilised 
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polyoxometalate-functionalised tyrosine-capped silver nanoparticles for a similar study, they 
showed toxicity against both Gram negative bacteria E. coli and Gram positive bacteria 
Staphylococcus albus, while showing no cytotoxicity against PC3 human epithelial cells 
[288]. It remains unclear at this stage whether the difference in Ag and Au toxicity profiles of 
nanoparticles with similar surface characteristics was due to differences in nanomaterial 
composition or to the difference in the mammalian cell line. Our current efforts remain 
focussed on attaining a better understanding of these fundamentally important questions 
[289]. 
 
Fig. 15. Schematic showing the relationship between antibacterial activity and surface 
functionalisation with the AuNPs synthesised by Daima et al. Reprinted with permission from 
[172]. Licensed under CC BY 2013. 
Biological media are buffered solutions containing a mixture of electrolytes and proteins 
which can interact with the nanoparticle surface [260]. While nanoparticles may be stable in 
situ for extended periods of time, this alone does not confer stability in cell culture media 
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[290, 291]. Alkilany and co-workers found that gold nanorods change surface charge when 
exposed to a cell culture medium due to proteins adsorbing to the surface. The group tested 
positively charged rods synthesised using CTAB, against rods which were identical before 
being coated with polyacrylic acid (PAA) to switch the surface charge [260]. The initial 
charge of the rod was shown to be irrelevant as all rods had high levels of BSA adsorbed on 
their surface, which at physiological pH has a negative charge [292]. With surface charge 
constant, the toxic effect observed from the positively charged gold nanorods was attributed 
to free CTAB remaining in the nanoparticle samples. To make this point, and demonstrate the 
relatively low importance of initial charge, the group coated the negatively charged, non-
toxic PAA-coated gold nanorods with positively charged polyallylamine hydrochloride 
(PAH). Unlike the positively charged CTAB rods, the PAH rods displayed negligible toxicity 
[260]. The group stressed the importance of studying the behaviour of nanoparticles after 
exposure to biological media as the nanoparticle-protein interaction is an important factor in 
uptake and toxicity.  
This suggests that the surface characteristics of AuNPs play a rather complex role in 
determining their mode of biological action. It remains almost certain that the surface 
characteristics of as-synthesised AuNPs are instantaneously modified on their contact with 
biological fluids or cell growth media. It is these modified surface characteristics that are 
responsible for AuNPs final mode of action. However, it should be possible to fine-tune the 
surface features of as-synthesised AuNPs such that their interaction with the biological fluids 
(before interacting with cells) can be finely controlled. The authors believe that this aspect 
has significant scope for future developments in the field, and have therefore elaborated on 
biological corona on the nanoparticle surface in Section 4.  
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AuNP 
shape 
AuNP size (nm) AuNP surface 
properties 
Experimental conditions Conclusions Reference 
Spheres 4, 12, and 18. 4 nm: cysteine and 
citrate. 
12 nm: glucose. 
18 nm: citrate, biotin, 
and CTAB. 
K562 leukaemia cell line. 
Toxicity measured using MTT.  
Uptake confirmed using TEM. 
Despite observing toxicity of 
precursors CTAB and AuCl4, when 
washed all particles were well 
tolerated. 
Connor et 
al. [257] 
2005 
Spheres 
and rods 
 
 
Spheres - 14, 30, 
50, 74 and 100. 
Rods - 40 x 14 
and 74 x 14. 
Spheres: citrate. 
 
Rods: CTAB replaced 
by citrate. 
HeLa cells. 
Uptake measured with ICPMS 
following 6 hour incubation. 
Toxicity measured using Trypan Blue 
Maximum uptake of 50nm spherical 
AuNPs.  
Rod-shaped AuNPs with lower aspect 
ratio showed greater uptake. 
No toxicity observed. 
Chithrani 
et al. [59] 
2006 
Spheres 
and rods 
Spheres: 5, 12, 
20, 30, 50 and 
70. 
Rod aspect 
ratios : 2.1, 2.5, 
3.0, 3.3 and 3.5. 
Spheres: citrate 
 
Rods: CTAB and PSS 
HaCaT cells. 
Toxicity measured using MTT. 
All spherical AuNPs were well 
tolerated. 
 
 
Wang et 
al. 2008 
[62]  
Rods 18 x 40. CTAB replaced with 
PSS, PDADMAC and 
PAH 
HeLa cells. 
Toxicity measured using Trypan Blue. 
Uptake measured using ICP-MS 
following 6 hour incubation. 
Low toxicity (≲20%) in all conditions. 
Negatively charged PSS coated AuNR 
showed lowest uptake. 
AuNRs coated in PSS followed by a 
layer of positively charged 
PDADMAC showed highest uptake. 
Hauck et 
al. [293] 
2008 
Spheres 13 and 45 Citrate Human dermal fibroblasts (CF-31) 
Uptake assessed using SEM following 
exposure for up to six days. 
45 nm AuNPs penetrate cells via 
clathrin-mediated endocytosis, while 
13 nm AuNPs enter via phagocytosis. 
Mironova 
et al. 
[275] 
2010 
Sphere 15 - 20  Aspartic acid, citrate 
and BSA 
Human fibroblast cell line (MRC-5) 
Cytotoxicity was measured using water 
Soluble Tetrazolium-1 assay.  
Oral toxicity was performed using a 
AuNPs were non-toxic to MRC-5 
cells.  
Citrate AuNPs caused a hepatotoxic 
and nephrotoxic response.  
Das et al. 
[187] 
2012. 
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murine model system.  Aspartic acid AuNPs caused 
hepatotoxicity. 
Spheres 11.7 and 13.5  Collagen (13.5) and 
PMA (11.7) 
Cervical carcinoma and lung 
adenocarcinoma cells. 
Toxicity measured using MTT. 
Uptake measured using ICP-MS 
following 4 hour incubation 
Collagen-coated gold NPs exhibit 
lower cytotoxicity, but higher uptake 
levels than PMA-coated gold NPs 
Marisca et 
al. [294] 
2015 
Spheres 2, 4, and 6 Cationic - thioalkyl 
tetra(ethylene 
glycol)ated 
trimethylammonium 
(TTMA),  anionic -  
carboxylate ligands 
(COOH) and 
zwitterionic AuNPs 
HeLa cells. 
Uptake measured using ICP-MS 
following 3 hour incubation 
For zwitterionic and anionic particles, 
uptake decreased with increasing 
AuNP size. For cationic particles, 
uptake increased with increasing 
particle size.  
Preliminary studies showed low 
cytotoxicity of all AuNPs tested. 
Jiang et al. 
[295] 
2015. 
Spheres 15, 50 and 100 "Bare gold" 
Negatively charged, 
used as purchased. 
Caco-2 cells. 
Uptake measured using ICP-MS 
following incubation periods of 1-24 
hours. 
As AuNP size decreased, the rate of 
cellular absorption increased, however 
cellular accumulation decreased. 
Furthermore, accumulation of AuNPs 
was found to be the cause of 
cytotoxicity observed. 
Yao et al.  
[296] 
2015 
Stars and 
spheres 
30 (stars) 
60 (spheres) 
HEPES buffered 
 
Human skin fibroblasts and rat fat pad 
endothelial cells. 
Toxicity measured using MTS. 
 
Spheres showed greater toxicity than 
stars in both cell lines. 
Spheres were more toxic to endothelial 
cells as compared to fibroblasts. 
Favi et al. 
[297] 
2015 
Table 2. Summary of uptake and toxicity studies of AuNPs of different shapes, sizes and surface coatings. PDADMAC - 
poly(diallyldimethylammonium chloride), PSS -  poly(4-styrenesulfonic acid), PAH -  poly(allylamine hydrochloride), PMA - poly(isobutylene-
alt-maleic anhydride), PSS - poly(styrenesulfonate)  
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4. Influence of biological protein corona formation on nanoparticle uptake and 
toxicity 
With intravenous injection the optimal route of administration for many AuNP based 
therapies, it is fair to assume that the blood will be the initial biological environment 
encountered by many of these nanoparticles. In the same way that other materials including 
medical implants become coated with proteins almost immediately after introduction to the 
blood [298], the competitive dynamic process of forming a protein corona commences at the 
nanoparticle surface almost instantaneously (Fig. 16). All inorganic nanoparticles, including 
gold, invoke the formation of a protein corona when introduced to protein containing 
solutions such as biological media or blood [68, 265, 291, 299]. The time dependant process 
begins in as little as seconds to minutes with proteins of high mobility localising on the 
surface of the particle forming what is termed a soft corona due to its transient existence. 
Over the following hours, proteins which are less mobile but carry higher affinity for the 
surface of the particle may replace the initial proteins to form a more permanent hard corona 
in what is known as Vroman’s effect [300].  
 
Fig. 16. The evolution of a protein corona begins almost immediately after introduction of a 
nanoparticle to protein rich conditions (I). Initially, the nanoparticle is covered with proteins 
which are abundant and highly mobile (II), the proteins species are exchanged over time 
resulting in hard corona of strongly bound proteins (III). Reprinted with permission from 
[301]. Copyright 2011 John Wiley & Sons. 
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To understand this effect, model proteins such as BSA or human serum albumin (HSA) are 
often used, as they represent albumin, the most abundant protein found in human blood. 
Despite the model used, the composition of the protein corona is unique, and influenced by 
many external variables relating not only to the nanoparticle itself, but also the nature of the 
biological system being probed. The composition of the protein corona is generally thought to 
consist of 10-50 proteins [265] and while highly abundant proteins in the blood such as 
albumin, immunoglobulin G (IgG), fibrinogen and apolipoproteins are most common 
constituents of the protein coronas studied to date, their relative abundance on the 
nanoparticle surface does not necessarily correlate with their natural abundance in the blood 
[302].  
While many mechanisms exist to explain the process of protein binding to the nanoparticle 
surface, the most widely accepted is the entropy-driven binding model [302, 303]. This 
exchange occurs because the release of water molecules from the area close to the 
nanoparticle surface is energetically favoured (due to high entropy increase) compared to the 
relatively small decrease in entropy caused by the binding of a protein in its place. 
It is thought that cellular-nanoparticle interactions are greatly dependant on the composition 
of the protein corona; and that the nanoparticle core, hydrophobicity, size, shape, charge and 
surface functionalisation elicit some effect on the types of proteins that are attracted to form 
the corona [301, 302]. It is widely accepted that the protein corona confers the nanoparticle 
its biological identity, and thus it can be suggested that the uptake of AuNPs by cells is 
dictated by the species of proteins, their orientation and arrangement on the surface of the 
nanoparticle [260, 304]. Understanding the relationship between causal factors and the final 
composition of the protein corona may therefore prove insightful to the unpredictable and 
often contradictory results obtained by researchers probing the toxicity of AuNPs.  
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4.1. Effect of nanoparticle size on protein corona formation 
The general paradigm linking nanoparticle size and protein corona formation is typically 
thought to hinge on the degree of curvature on the nanoparticle surface [68, 280, 298, 305, 
306]. This is most commonly probed by examining spherical particles of different diameters, 
and comparing to binding observed on macroscopic flat surfaces of similar surface chemistry 
[299, 307-310]. Geometrically, it can be understood that differences in the degree of 
curvature may favour or inhibit proteins depending on their three dimensional structure, 
allowing for certain proteins to make contact with a greater area of the particle offering 
greater stability, or sterically inhibiting or possibly disrupting others upon making contact 
[305, 308, 311]. The knowledge that curvature is influential on protein-nanoparticle 
interactions is seemingly universal for all nanoparticles; however with respect to the protein 
perspective the results are less predictable. Having a large degree of variation in size, 
structure and composition between various proteins, the interactions must be probed or 
modelled for each protein and nanoparticle in question taking into account such variables as 
the preferred structure of each protein as well as the position and number of binding sites 
available on the nanoparticle surface. It must be noted that even with this knowledge, 
assessing the binding of each protein alone does not necessarily provide transferable 
information related to binding affinity of the proteins in a highly dynamic environment as 
would be expected within the blood.  
Size dependant effects have been seen in many nanoparticles despite their elemental 
composition. For instance, Shang and co-workers examined the behaviours of cytochrome c 
proteins on the surface of different sized silica nanoparticles. Their finding showed that the 
cytochrome c structure became increasingly distorted upon binding to larger silica 
nanoparticles, while also becoming increasingly unstable in its new conformation [312]. 
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Conversely, Roach and co-workers found that the structure of albumin becomes increasing 
disordered after binding to larger silica nanoparticles while fibrinogen becomes increasingly 
compromised upon binding to smaller particles with higher surface curvature [308] (Fig. 17). 
Such size dependant effects were also recorded by Dobrovolskaia and co-workers in the case 
of 30 and 50 nm AuNPs with 30 nm particles binding to a greater range of protein species 
when compared with the 50 nm particles of similar surface chemistry [313]. 
 
Fig. 17. Schematic showing how the size of a spherical particle (and thus the degree of its 
surface curvature) can affect the structure of bound proteins. While the structure of albumin 
becomes increasing disordered after binding to larger silica nanoparticles, fibrinogen 
becomes increasingly compromised upon binding to smaller particles which possess higher 
surface curvature. Reprinted with permission from [308]. Copyright 2006 American 
Chemical Society. 
While it is clear that the composition of the corona is influenced by nanoparticle size, the 
question remains how to maximally manipulate this effect for therapeutical gain. For 
therapies that rely on long circulation times, avoiding nonspecific uptake of nanoparticles by 
the immune system, more specifically, the reticuloendothelial system (RES) and the 
mononuclear phagocyte system (MPS), is critical [283, 314, 315]. It is known that certain 
proteins within the blood act as flags for the RES and MPS systems; such proteins are termed 
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opsonins (and their binding to the nanoparticle surface, opsonisation) and they provide the 
link between a nanoparticle and its capture by the MPS system [315-318]. Known opsonins 
include certain immunoglobulins (IgG and IgM), specific complement proteins (most notably 
C3), von Willebrand factor, thrombospondin, fibronectin, and mannose-binding protein. 
Conversely, other classes of proteins coexist that are deemed dysopsonic due to their 
opposing effect, suppressing the recognition and elimination of opsonised entities by the RES 
and MPS. PEGylation or the process of coating an object with linear chains of covalently 
attached PEG macromolecules is commonly employed for in vivo application of AuNPs to 
minimise such unwanted effects. As well as improving biocompatibility, PEGylation also 
decreases the extent of protein adsorption thus decreasing the risk of opsonisation [182, 315, 
319]. The process of PEGylation and its subsequent effect on nanomaterials has already been 
discussed in a number of outstanding reviews [182, 320-323]. 
An extensive study in this field performed by Casals and co-workers utilised citrate stabilised 
AuNPs in sizes ranging from 4-40 nm to probe the size effect on protein corona formation, 
with particular emphasis on the density and persistence of both hard and soft coronal states. 
The group found that 4 nm AuNPs were not able to form a stable protein corona despite 
prolonged incubation times, consistent with the hypothesis that particles of this size do not 
notably activate RES or MPS [68, 306]. The 10 nm AuNPs behaved as expected for particles 
of this size, forming an initial transient soft corona followed by a persistent hard corona at 
longer incubation times. The largest 40 nm particles examined in this study initially behaved 
like 10 nm particles, forming a soft corona transitioning into a hard corona over time; 
however the hard corona which formed on the 40 nm particles was both less dense and less 
strongly bound compared to the 10 nm particles. The group concluded that a particle of 10 
nm is ideally sized for optimal protein coverage, being of a comparable size to the most 
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abundant serum proteins (albumins) while the 40 nm particles exceed the ideal size for serum 
protein binding, and were more prone to opsonisation [68]. 
In contrast to these trends, Lacerda and co-workers probed the kinetics of specific serum 
proteins such as albumin, fibrinogen, γ-globulin, histone and insulin, monitoring their binding 
on citrate stabilised AuNPs of sizes from 5-100 nm. Their findings highlighted a trend of 
increasing nanoparticle-protein binding strength with increasing nanoparticle size, until the 
size reached 60 nm, after which the trend dissipated. The cooperativity of the binding, i.e. the 
affinity of a particular protein for a nanoparticle after binding by successive proteins, 
decreased with nanoparticle size in all cases except insulin. These discrepancies draw 
attention to difficulties encountered by researchers in this area, whereby information gained 
by examining proteins individually does not necessarily correlate to results obtained in a 
competitive binding environment [324]. 
Walkey and co-workers examined citrate stabilised AuNPs ranging in size from 15-90 nm 
after grafting with 5 kDa PEG on the AuNP surface with varying density. By altering the 
PEG-AuNP ratio during grafting, PEG densities ranging from 0-1.25 PEG/nm2 were 
achieved. The study revealed two relationships, viz. a correlation between decreasing AuNP 
size and increased adsorption of serum proteins, as well as decreased adsorption of serum 
protein with increasing PEG grafting density. They reasoned that a decrease in nanoparticle 
size is synonymous with an increase in curvature on the surface of the nanoparticle, allowing 
better accommodation of PEG molecules with increased space, as opposed to the larger 
particles that forced a more crowded layer of PEG molecules. The fanned out arrangement of 
PEG molecules was claimed to lower the thermodynamic barrier for protein adsorption, 
leading to increased protein binding [309].  
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AuNP size 
(nm) 
AuNP 
characteristics 
Conclusion Reference 
5, 10, 20, 30, 
60, 80 and 100 
Citrate stabilised 
spherical AuNPs 
Increased nanoparticle-protein 
binding strength observed with 
increasing AuNP size (up to 60 
nm). 
Cooperativity of binding 
decreased with AuNP size in all 
cases except insulin. 
Lacerda et al. [325] 
2009 
30 and 50 Citrate stabilised 
spherical AuNPs 
30 nm particles bound to a 
greater range of protein species 
as compared to the 50 nm 
particles of similar surface 
chemistry. 
Dobrovolskaia et 
al. [326] 2009 
4, 10, 13, 16, 
24, and 40 
Citrate stabilised 
spherical AuNPs 
10 nm AuNP is ideally sized for 
optimal protein coverage. 
40 nm AuNP exceeds the ideal 
size for serum protein binding. 
Casals et al. [68] 
2010 
15, 30, 60, and 
90 
Citrate stabilised 
PEGylated 
spherical AuNPs 
Decreased AuNP size lead to 
increased adsorption of serum 
proteins. 
Increased PEG grafting density 
decreased adsorption of serum 
protein. 
Walkley et al. 
[309] 2012 
Spheres: 20 
and 30 
Rods: Aspect 
ratio 4 and 20 
CTAB capped 
spherical and rod 
shaped AuNPs 
Protein corona formation was 
detected on the surface of 
AuNPs, regardless of size and 
shape. 
Mirsadeghi et al. 
[327] 2015 
Table 3. Summary of studies examining the effect of AuNP size on protein corona formation. 
4.2. Effect of nanoparticle shape on protein corona formation 
In a similar way that the size of a nanoparticle affects protein corona formation, shape plays 
an important, albeit less understood role. Much of the shape related effects on protein corona 
formation are indirectly gained though uptake studies, monitoring cell-nanoparticle 
interactions and inferring the state of the protein corona from these results [59, 185, 280]. 
Despite the small number of studies in this area, it is generally agreed that shape affects the 
manner in which a protein can bind to the surface of a nanoparticle, with the introduction of 
such features as curvature, flat planes, sharp edges, corners, and pores on various shapes. 
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Such features may favour or hinder binding of individual proteins depending on their 
conformation, or cause them to undergo structural changes [265]. 
Ramezani and co-workers performed a molecular dynamic simulation to compare the binding 
of HSA protein to cubic and spherical AuNPs with similar surface areas. The data showed 
that binding to cubic AuNPs causes the albumin to unfold more significantly than it does with 
spherical particles. Interestingly, the simulation showed that the distance between HSA 
molecules on the cubic AuNPs was larger than on the spherical AuNPs, highlighting that the 
unfolding effect is much stronger for cubic AuNPs than spherical AuNPs. The group also 
noted changes in the secondary structure of HSA upon binding to cubic particles, an effect 
not observed with spherical AuNPs. The authors reasoned that the curvature of spherical 
particles allows proteins to preserve their original structure by permitting greater gyration of 
the protein after binding, whereas a flat surface (consistent with the facets of a cubic particle) 
would not allow such movements [328]. 
Gagner and co-workers synthesised both spherical and rod shaped AuNPs using two 
enzymes, lysozyme and α-chymotrypsin, to monitor the structure and function of proteins 
after adsorption. They showed that higher density adsorption occurs on the surface of gold 
nanorods, as compared with spherical AuNPs, which they attributed to the long cylindrical 
surface of gold nanorods. When examining lysozyme, the group noted a higher degree of 
secondary structure disruption on rods, as compared with spheres (15% and 10%, 
respectively). Conversely, α-chymotrypsin was capable of retaining its secondary structure at 
low levels of coverage on both shapes, however as coverage became denser; a 40% loss of 
secondary structure was detected. Of particular interest is the fact that the change in α-
chymotrypsin’s secondary structure led to an 86% reduction in activity [329].  
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Focussed on the link between nanoparticle shape and the stability of a bound protein, Asuri 
and co-workers compared the binding of enzyme soybean peroxidise with the surface of C-60 
fullerenes and with flat graphite flakes. The group noted that upon binding to the highly 
curved surface of the fullerene, the enzyme possessed much greater stability with an 
enhanced (2.5 times) half-life, leading to enhanced enzymatic activity as compared to the flat 
supports. The authors hypothesised that the effect of enhanced stability on highly curved 
surfaces may not be limited to carbon and could apply to other materials including gold 
[310]. 
Investigating rod shaped particles, Gagner performed ligand exchange to remove CTAB from 
the nanoparticle surface, and reasoned that the increased binding they observed on gold 
nanorods was due to their long cylindrical surface [329]. Conversely, Caswell [330] and 
Chang [331] (Fig. 18) probed protein binding on as-synthesised rods obtained using CTAB. 
Both groups found that protein adsorbed preferentially to the ends of the rod shaped particles, 
and suggested that this may be due to the CTAB being tightly packed on the less highly 
curved long dimension, which may inhibit protein binding. With this knowledge, Chithrani 
and Chan examined rods coated with transferrin, a blood plasma protein vital in iron 
transportation [280]. They found that rods with lower aspect ratios displayed a higher degree 
of binding compared to rods with high aspect ratios. They reasoned that this finding, in 
agreement with Casswell and Chang, was due to increased curvature on the ends of the lower 
aspect ratio rods, and could also lead to more strongly bound proteins in these areas [280]. 
The effects reported for other materials are consistent with the findings for gold, suggesting 
that they are true shape effects, and not necessarily related to the core material. Deng and co-
workers examined TiO2 nanorods, nanotubes and nanospheres [332]. Consistent with many 
gold related reports, their results showed that nanospheres bound to higher amounts of protein 
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compared to both rods and tubes. The most interesting result was the comparison of protein 
species found on the TiO2 rods and tubes, with IgM and IgG the major constituents of the rod 
corona, while fibrinogen was the major constituent of the nanotube corona. With 
immunoglobulins IgM and IgG being known opsonins, this study highlights shape to be an 
important consideration for potentially avoiding nanoparticle detection by the immune system 
[265, 307]. 
 
Fig. 18. TEM images of gold nanorods assembled end-to-end after exposure to mouse 
antibody/antigen biomolecules. By varying the concentration of biomolecules, chains of 
increasing length are assembled. Reproduced with permission from [331]. Copyright 2005 
The Royal Society of Chemistry. 
It is possible however that shape may not have such noticeable effects in all settings. One 
study which did not see any significant shape related effects was conducted by Boulos and 
co-workers who examined gold nanorods of aspect ratios 3.5 and 18, along with 20 nm 
spherical AuNPs. They studied the particles after they were coated with PEG, as well as after 
a polyelectrolyte coating that was used to recreate the original cationic state seen in CTAB 
synthesised particles. They found that PEG did not prevent binding of BSA protein to any 
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particle, and all PEGylated particles showed cooperative binding regardless of nanoparticle 
shape. BSA was shown to have a higher affinity for polyelectrolyte coated particles which 
possessed a strongly positive surface charge, and this remained true of both shapes studied 
[333]. 
AuNP 
shape 
AuNP characteristics Conclusion Reference 
Spheres 
and rods 
Transferrin coated 14 
and 50 nm spherical 
AuNPs. CTAB 
stabilised, transferrin 
coated AuNRs 20 x 30, 
14 x 50 and 7 x 42 nm 
Proteins adsorbed only onto the ends 
of the AuNRs due to residual CTAB. 
AuNRs with lower aspect ratios 
displayed a higher degree of binding 
compared to AuNRs with high aspect 
ratio 
Chithrani and 
Chan [280] 
2007 
Spheres 
and rods 
CTAB stabilised 10nm 
spheres and  
CTAB stabilised 
AuNRs 10 x 36 nm  
Higher density protein adsorption 
occurs on the surface of AuNRs. 
More significant lysozyme secondary 
structure disruption to observed upon 
interaction with AuNRs 
Gagner et al.  
[329] 2011 
Spheres 
and rods 
PEG and 
polyelectrolyte coated 
20nm spherical AuNPs 
and AuNRs of aspect 
ratios 3.5 and 18. 
No significant shape related effects 
observed 
Boulos et al.  
[333] 2013 
Spheres 
and cubes 
Cubic AuNP with 80 
nm side length and 
60 nm spherical AuNP 
Molecular dynamic simulation 
showed distance between HSA and 
cubic AuNPs was larger than with 
spherical AuNPs. Curvature of 
spherical particles allows proteins to 
preserve their original structure after 
binding. 
Ramezani et 
al. [328] 
2014 
Spheres 
and rods 
CTAB capped AuNPs.  
20 and 30 nm spherical 
AuNPs. AuNRs of 
aspect ratios 4 and 20. 
Protein corona formation was 
observed on the surface of AuNPs, 
regardless of size and shape. 
Mirsadeghi et 
al. [327] 
2015 
Table 4. Summary of studies examining the effect of AuNP shapes on protein corona 
formation. 
4.3. Effect of nanoparticle surface characteristics on protein corona formation 
The effect of the surface characteristics of nanoparticles on the formation a protein corona 
may be examined with varying levels of subtlety. The most fundamental aspect may involve 
comparison of the protein corona formed around nanoparticles of different inorganic 
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compositions. Deng and co-workers analysed the composition of the protein coronas which 
formed on two commonly used metal oxide particles of comparable size and surface charge, 
viz. ZnO (31 nm diameter, -24 mV zetapotential) and TiO2 (30 nm diameter, -26 mV 
zetapotential). The group found that the elemental core of the nanoparticle influenced both 
the species and concentration of bound proteins with dramatically different coronas 
elucidated from each nanoparticle [332].  
The next layer of subtlety is surface coating or functionalisation, a practice often employed to 
fine-tune parameters such as biodistribution, circulation, accumulation and clearance of 
nanoparticles in drug delivery systems [302, 317]. In addition to their study on different sized 
AuNPs, Casals and co-workers studied the effect that surface functionalisation of AuNPs had 
on the formation of a protein corona. The group examined the protein coronas that formed on 
citrate stabilised AuNPs of sizes 4-40 nm, comparing them with those formed after 
modification of the nanoparticles with a self-assembled monolayer carrying a net positive 
(aminoundecanethiol) or negative (mercaptoundecanoic acid) charge. The group found that 
the negatively charged nanoparticles were unable to form a hard corona, with the loosely 
bound soft corona washing off easily despite an extended incubation period in cell culture 
medium. Conversely, the positively charge particles formed a soft transient corona more 
rapidly, driven by electrostatic forces between the positively charged surface and negatively 
charged proteins in the media. In this case, the soft corona possessed higher stability than the 
hard corona (formed on the citrate stabilised AuNPs), and was persistent after purification 
[68].  
Exploring the effects of spherical nucleic acid (SNA) nanoparticles, Chinen and co-workers 
used SNAs with an AuNP core, surface modified with a 3' thiol-modified guanine-rich 
sequence to observe if the three-dimensional structure of the oligonucleotides impacted on 
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the structure and composition of the proteins that bind to the surface of the particle. The study 
revealed that the structure of the chosen oligonucleotide can dictate the protein species that 
binds to the surface. The altered corona was shown to impact on the cellular uptake of the 
particles, showing increased macrophage uptake. These findings are particularly relevant in 
terms of nanotherapeutics development, where rapid blood clearance or increased cellular 
uptake is desired [334].  
These findings are consistent with many other groups that have investigated the protein 
coronas which form on AuNPs after PEGylation. The process is commonly employed for in 
vivo application of gold nanorods, to avoid the potential toxicity derived from CTAB 
persistent on the surface after synthesis. While PEGylation of gold nanorods is performed as 
a way of ensuring biocompatibility, its presence is known to cause a reduction in uptake for 
the reasons described above. The complications surrounding this depend on the intended fate 
of the nanoparticle with a potential trade-off between longevity within the bloodstream and 
the likely degree of uptake. The ‘hydrophilic stealth coating’ that PEG molecules form 
around the particle [309, 319, 335], may protect it from elimination via immune intervention, 
but may also reduce uptake by cells via the same mechanism [59, 185].  
Cui and co-workers compared the protein coronas which formed on nanoparticles with 
various surface modifications, such as citrate, thioglycolic acid, cysteine and PEG with 
varying molecular weights of 2 and 5 kDa. The 5 kDa PEGylated particles were unable to 
from a protein corona in any of the protein environments studied, while the 2 kDa PEGylated 
particles showed protein corona formation in BSA, but not with transferrin or fibrinogen 
[336]. This finding is consistent with the work of Cruje and Chithrani [337] as well as 
Dobrovolskaia and co-workers [326] who found that the amount of protein bound in the 
corona may be influenced by the molecular weight (i.e. chain length) of the PEG molecules 
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within the AuNP coating, with longer PEG chain lengths consistent with lower levels of 
protein interaction with the nanoparticle surface (Fig. 19). 
Walkey and co-workers compared the protein corona composition between citrate-capped 
AuNPs and PEGylated citrate-capped AuNPs. Complement protein C3 was detected at levels 
of 30% w/w on the unmodified AuNPs, reducing to a level of 5% w/w after PEGylation, 
showing that modification was sufficient to significantly reduce, but not totally eliminate, 
opsonisation [309]. 
 
Fig. 19. Graph showing the extent of bound proteins to 30 nm AuNPs uncoated or coated 
with PEG molecules of different molecular weights over time. Coating the AuNPs with longer 
PEG chain lengths leads to lower levels of bound protein. Reprinted with permission from 
reference [326]. Copyright 2014 Elsevier Inc. 
Surface 
Functionalisation 
AuNP 
Characteristics 
Conclusions Reference 
Citrate AuNPs 
modified with 
aminoundecanethiol 
and 
mercaptoundecanoic 
acid 
4, 10, 13, 16, 24, 
and 40 nm 
spherical AuNPs 
Negatively charged AuNPs were 
unable to form a hard corona. 
Positively charge AuNPs formed a 
soft transient corona more rapidly. 
Casals et 
al. [68] 
2010 
Citrate and PEG 15, 30, 60, and 
90nm spherical 
AuNPs 
Complement protein C3 was 
detected at higher levels on 
unmodified AuNPs, compared with 
PEGylated AuNPs. Modification was 
Walkey et 
al. [309] 
2012 
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sufficient to significantly reduce, but 
not totally eliminate, opsonisation. 
Citrate, thioglycolic 
acid, cysteine and 
PEG 
38 nm spherical 
AuNPs 
5 kDa PEGylated particles were 
unable to from a protein corona in 
any of the protein environments 
studied. 
2 kDa PEGylated particles showed 
protein corona formation in BSA, but 
not with transferrin or fibrinogen 
Cui et al. 
[336] 2014 
Citrate and lipoic 
acid  
40 nm spherical 
AuNPs 
No significant surface chemistry 
related effects.  
HSA and IgG formed coronas over 
both AuNPs, while fibrinogen caused 
agglomeration in both. 
Sasidharan 
et al. [338] 
2015 
Table 5. Summary of studies examining the effect of AuNP surface functionalisation on 
protein corona formation. 
5. Technological advances in the use of gold nanoparticles 
The use of gold to promote good health has been documented in literature dating back to at 
least the 1st century, when Pliny detailed its multiple functions in what is now regarded as the 
one of the earliest encyclopaedias ever compiled - Naturalis Historia [1]. Listed for both its 
medical and magico-religious properties, gold is described as being both a cure for fistulas, 
haemorrhoids and warts as well as an amulet to be worn for protection against harmful 
charms [1, 339].  
Predating this publication, the use of gold as a purifying tonic or elixir by the Egyptians [2] 
and more tangibly the appliance of flat gold bands as dental prosthetics by the Etruscans [3] 
is believed to date back to the thirtieth century B.C. and the seventh century B.C., 
respectively. The Vedic age of ancient India (ca.1750–500 B.C.) saw gold utilised as a 
therapy for memory loss, poor eyesight and infertility and since the 8th century the use of 
Swarnabhasma (swarna means gold, and bhasma means ash) or gold ash (a nanoparticulate 
form of gold) began, a practice which is still continued by Ayurvedic followers to treat 
asthma, autoimmune and nervous disorders [340, 341]. During the Renaissance, physician 
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and alchemist Paracelsus revived the idea of using gold as a medicine when he created Aurum 
Potabile, a colloidal gold suspension which he prescribed for sufferers of epilepsy [4]. 
Today, the use of AuNPs for biotechnological and medical advancement is progressing 
rapidly with biosensors, bioimaging techniques and therapeutic agents dependant on the 
unique properties of AuNPs beginning to pass clinical phase trials with countless more in 
development.  
5.1 	Gold nanoparticles as diagnostic agents 
Comprising both in vitro and in vivo applications, the use of AuNPs as biosensors is 
widespread, owing to the interesting SPR behaviour of AuNPs in varied environments [342]. 
Some examples of the use of AuNPs include sensors for bacteria [343-345], early cancer 
markers [346], and specific biomolecular interactions [347]. 
It is not widely known, but AuNPs have formed the basis of home pregnancy tests such as 
Carter Wallace’s “First Response” since the early 1990’s. Utilising the aggregation tendency 
of AuNPs, the tests combined micrometre sized latex particles and AuNPs functionalised 
with different epitopes of human chorionic gonadotropin antibodies. When the gonadotropin 
hormone present in the urine of woman during pregnancy, contacts AuNPs within the sensor, 
the particles agglomerate forming visible pink aggregates [348]. Working via a similar 
principle, ImmunoCAP (Phadia, Inc) is a commercially available allergy test which uses 
whole blood samples to create an immunoglobulin E (IgE) profile [349]. The test is used to 
differentiate allergy like symptoms (such as bronchospasm, rhinitis, conjunctivitis, eczema, 
angioedema, and nausea) and helps to provide a clinical diagnosis to a specific allergen. 
Preloaded with 10 common allergens including pet hair, pollen and dust mites, once blood is 
added, if IgG antibodies are present in the blood, they bind to the specific sections of the test 
strip containing the relevant allergen. The developer solution containing dried gold-anti-IgE 
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conjugate is then released indicating an allergy to a particular trigger by forming pink/red 
lines due to the formation of complexes between the AuNPs and bound IgE antibodies. 
Similar principle is utilised by many other tests for detection of polynucleotides [350], 
proteins [351], antiproteins [352] and heavy metals [353]. 
Working via a different principal, SoPRano (ParmaDiagnostics, Belgium) uses localised 
surface plasmon resonance (LSPR) to detect and quantify binding effects which occur on the 
surface of AuNPs [354]. Using negatively charged AuNRs, the system can be used to probe 
biomolecular interaction kinetics, antibody detection and blood brain barrier permeability. By 
first coating the rods with a biomolecule of interest and exposing them to different 
concentrations of analyte, the interaction causes a measurable difference in the absorbance 
value or an LSPR shift, which can be read using an absorbance plate reader. 
As an alternative to methods which require a ‘lock and key’ approach to sensing (where 
specific recognition between analyte and receptor must takes place), the ‘chemical nose’ 
approach uses an array of AuNPs as receptors for protein analysis [355], and clinical 
diagnostics [356-358]). The technique uses the interaction between a fluorescent polymer and 
an array of AuNPs with various surface characteristics (such as surface charge and surface 
functional groups). While the polymer’s fluorescence is quenched when attached to the 
AuNPs, once dissociated through competitive binding of proteins to certain AuNPs, a 
fluorescence pattern is generated (Fig. 20). This pattern can be analysed to detect individual 
proteins and differentiate between protein species, giving both quantitative and qualitative 
data. The Rotello research group has made significant progress in this area, detecting and 
differentiating between bacterial strains [359], quantifying proteins [355, 360, 361], and 
identifying cancerous cells [362] [363].  
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Fig. 20. Schematic depicting a nanoparticle-conjugated polymer sensor array, wherein (a) 
anionic conjugated polymers bound on to cationic AuNPs are displaced by negatively 
charged bacteria surfaces, and (b) a fluorescent pattern is generated during the polymer 
displacement process by the bacteria. Reprinted with permission from [359]. Copyright 2008 
John Wiley & Sons. 
Another notable breakthrough in this area is the potential for diagnosis of lung cancer using 
the exhaled breath of subjects. While most published methods are performed with liquid 
samples (generally blood), the non-invasive method developed by Peng et al. requires the 
collection of exhaled air from patients to detect specific volatile organic compounds (VOCs) 
which have been linked to the presence of lung cancer at certain concentrations [357]. The 
group has since identified VOCs which are markers for breast, colorectal, prostate, head and 
neck cancers, and further developed exhaled breath analysis sensors for these VOCs with 
AuNP arrays [356, 358]. 
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Combining the expanding field of genomic medicine with nanodiagnostics, Halo et al. 
developed the NanoFlare system to detect live cancer cells circulating within the blood. The 
system, which features a spherical gold nanoparticle conjugated with single-stranded DNA, 
was found capable of detecting metastatic activity at early stages by attaching to mRNA on 
the target gene. This binding activity facilitated the release of a fluorescently labelled 
"reporter flare" which could be detected using flow cytometry down to the single cell level. 
The significance of this technique extends beyond its diagnostic potential, as following 
detection assay, the cells could potentially be isolated and cultured allowing genetic analysis 
of the cancer, a potential breakthrough for personalised medicine. [364] 
Diagnostic 
Target 
AuNP Diagnostic mechanism Reference 
ImmunoCAP 
allergy test 
AuNPs 
functionalised with 
anti-IgE conjugates 
IgG antibodies present in the blood, 
bind to the specific sections of the test 
strip containing the relevant allergen.  
Allergies are indicated by pink/red 
lines due to the formation of a 
complex between AuNPs and IgE 
antibodies. 
Ewan and 
Coote [349] 
1990 
“First 
Response” 
pregnancy test 
AuNPs 
functionalised with 
epitopes of human 
chorionic 
gonadotropin 
antibodies 
Gonadotropin hormone contacts 
AuNPs causing particles 
agglomeration forming visible pink 
aggregates. 
Bangs 
[348] 1996 
Polynucleotide 
detection for 
diagnosis of 
genetic disease 
13nm spherical 
AuNPs modified 
with 
mercaptoalkyloligo
nucleotide 
Multistep process to colorimetrically 
detect specific polynucleotides which 
form coloured complexes with 
mercaptoalkyloligonucleotide 
modified AuNPs. 
Elghanian 
et al. [350] 
1997 
Aggregation 
based protein 
sensor 
AuNPs conjugated 
with p-
aminophenyl-â-D- 
lactopyranoside 
(Lac). 
Lac-conjugated AuNPs aggregate 
when exposed to Recinus 
communis indicated by a colour 
change from pinkish-red to purple. 
Otsuka et 
al. [351] 
2001 
Colorimetric 
detection of 
heavy metal 
ions 
13nm AuNPs 
capped with 11-
mercaptoundecanoi
c acid 
 
Aggregation of AuNPs in the presence 
of heavy metals detected by a visible 
colour change. 
Kim et al. 
[353] 2001 
Aggregation 10 nm AuNPs Aggregation of AuNPs in the presence Thanh and 
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based antibody 
sensor. 
coated with protein 
antigens 
of their corresponding antibodies 
causes a shift in absorption maximum 
from 620 nm. 
Rosenzweig 
[352] 2002. 
Chemical nose 
for protein 
analysis and 
clinical 
diagnostics 
Array of AuNPs 
with varied surface 
characteristics 
(such as surface 
charge and surface 
functional groups). 
Fluorescence pattern is generated after 
the displacement of fluorescent 
polymers from the AuNP surface  
You et al. 
[355] 2007 
 
 
Chemoresistor 
breath test for 
cancer 
diagnosis 
5-nm AuNPs  
capped with  
different organic 
functionalities 
Detection of volatile organic 
compounds which are markers for 
certain cancers by measuring changes 
in resistance in the presence of analyte. 
Peng et al. 
[357] 2009 
Biomolecular 
interaction 
kinetics, 
antibody 
detection and 
blood brain 
barrier 
permeability 
probe 
SoPRano AuNRs. 
Negatively charged 
AuNRs with 
specific 
biomolecular 
coating 
Interaction between the AuNRs and 
analyte causes an LSPR shift, read 
using an absorbance plate reader. 
Dell  et al. 
[354] 2012. 
Detection of 
live cancer 
cells within the 
blood 
NanoFlare 
spherical AuNP 
conjugated with 
single-stranded 
DNA 
AuNP attached to mRNA on the target 
gene. The binding activity facilitates 
the release of a fluorescently labelled 
"reporter flare" detected using flow 
cytometry. 
Halo et al. 
[364] 2014 
Table 6. Summary of the application of AuNPs as diagnostic agents. 
5.2 Gold nanoparticles as therapeutic agents 
The area of AuNPs as therapeutic agents is both diverse and rapidly growing. Researchers are 
attempting to treat HIV [365], bacterial infections [366], inflammations [367] and coronary 
diseases [368] with AuNP based therapies; however anticancer activities [12, 186, 190, 229, 
369-379] forms the bulk of the research. While both aurous (AuI]) and auric (AuIII) gold 
complexes are commonplace in pharmaceuticals [380, 381] [273, 382], the prevalence of 
AuNP (Au0) based therapies is far less common. Presented in this review are the AuNP based 
therapies that are approaching or have progressed to clinical trial phase. 
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Possibly the first AuNP based therapy to reach (and pass) Phase I clinical trials, CYT-6091 is 
a 27 nm citrate stabilised AuNP surface functionalised with both tumour necrosis factor-α 
(TNF-α) and thiolated PEG [377]. The antitumor effects of TNF-α (more specifically 
recombinant human TNF – rhTNF) have been known for decades; however its severe toxicity 
in humans has previously limited its dosage [379]. TNF-α acts in multiple capacities acts as a 
proinflammatory cytokine, to disrupt tumour vasculature and when used in combination with 
chemotherapy, allows the subsequent treatment to penetrate tumours more effectively 
eliciting greater results. The therapy first developed in 2004 by researchers as Aurimune by 
CytImmune Sciences Inc. (Rockville, MD, USA) [191] achieves circumvention of RES 
uptake, leading to increased circulation time in part due to its surface PEGylation, which was 
also shown to reduce the expected toxicity of rhTNF, and increased its accumulation inside 
the tumours rather than in the surrounding tissues. This study used thiolated AuNPs as the 
vehicle for the therapy due to the strong binding affinity for rhTNF, noting that the AuNP 
bound rhTNF had a 5 fold longer half-life in plasma than native rhTNF. It was also noted that 
AuNPs restricted the biodistribution of the treatment, showing greater specificity for targeted 
tumour sites, and their notable absence in healthy tissues. This allowed higher doses to be 
administered with reduced incidence of adverse side effects and systemic toxicity. After 
progressing through Phase I clinical trials, CYT-6091 is proposed to be next used to treat 
non-small lung cancer in combination with chemotherapy as part of Phase II trials [377]. 
Harnessing the SPR effects of AuNPs, researchers are employing plasmonic phototherapy to 
treat cardiovascular disease as an alternative to statin based therapy. Notably while statin 
therapy is successful in lowering cholesterol, its effectiveness in inducing atheroma (plaque) 
regression is less clear [383]. The research group led by Khalamov developed a plasmonic 
nanophotothermic treatment consisting of allogenic stem cells containing gold-coated silica 
nanoparticles [384]. The human study, which was preceded by an animal study using 
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miniature swine [368] recruited 180 patients, of which 60 were given the silica-AuNP 
treatment to allow comparison to more conventional techniques. The nanoparticles were 
administered through a patch implanted into the affected artery and 7 days post-surgery, 
irradiation of the particles with near-infrared (NIR) irradiation took place (821 nm, 35–44 
W/cm2, 7 minutes). Due to the maximum light absorption by these particles in the NIR 
region, the absorbed photo-energy is converted into thermal energy, which in turn burns the 
surrounding tissues; in this case, the atheroma. This technique, which is referred to as nano-
burning, saw success in Phase I trials with significant atheroma regression observed, though 
the second planned trial has been discontinued [385].  
Cofounded by Naomi Halas, part of the team responsible for the invention of gold nanoshells 
for NIR therapy [386], Nanospectra Biosciences Inc. (Houston, TX) has focused their efforts 
over the past decade on the development of AuroLase therapy. The photothermal therapy 
which utilises AuroShell particles comprising of a 120 nm silica core surrounded by a 15 nm 
outer gold shell is used in combination with NIR irradiation to treat head and neck tumours. 
The nanoparticle treatment is delivered intravenously and shows accumulation in solid 
tumours due to the enhanced permeability and retention (EPR) effect of solid tumours 
because of their abnormally formed vasculature and poor drainage [387]. After sufficient 
accumulation of AuroShells (generally occurring 12-24 hours post-infusion), the area is 
illuminated by an 808 nm wavelength laser causing the nanoparticles to heat up, effectively 
burning the tumour. The FDA-approved pilot study was completed showing promising results 
with Phase II trials planned to target metastatic lung cancer [388]. 
Besides phototherapy, radioisotopes of gold have also been exploited for imaging and therapy 
of cancers. The low (Au199: βmax - 0.46 MeV; half-life - 2.7 days), and moderate (Au198: βmax - 
0.96 keV; half-life 3.2 days) energy beta particles emitting isotopes, due to their desirable 
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half-life characteristics offer ideal opportunities for radioimaging (Au199) and therapy (Au198). 
To circumvent the limitations associated with traditional metal based radiopharmaceuticals, 
nanoparticles of gold have been employed as radioactive probe for imaging and radiotherapy 
of solid tumours [389]. Several groups have demonstrated the utility of radioactive AuNPs-
based nanodevices in targeted radiopharmaceutical dose delivery to the tumours [53, 98, 
390]. In a pioneering study, Shukla et al recently reported a AuNPs-based targeted 
radiopharmaceutical approach towards radiotherapy of prostate cancer [53]. This method 
demonstrated rapid, room temperature synthesis of 198AuNPs using epigallocatechin gallate 
(EGCG), a clinically-approved phytochemical from green tea. These EGCG-reduced 
radioactive AuNPs were amenable to facile manipulation of radioactive dosage within the 
nanoparticle matrix, offering a simple tool with potential for clinical translation. Since EGCG 
can target a 67 KDa receptor protein (Lam 67R) overexpressed on cancer cells, these 
nanoparticles exhibited selective uptake in prostate cancer cells. These nanoparticles showed 
remarkable stability in blood plasma and a desirable biodistribution profile in prostate tumour 
bearing mice, leading to ~80% reduction in tumour volume. The levels of white blood cells, 
red blood cells, platelets and lymphocytes were found comparable to the control groups, thus 
supporting high therapeutic efficacy of these radioactive 198AuNPs. 
Therapeutic 
Target 
AuNP Therapeutic mechanism Reference 
NIR irradiation 
to treat head and 
neck tumours 
AuroShell -120 nm 
silica core particle 
surrounded by a 15 
nm outer gold shell 
Following intravenous nanoparticle 
administration, particles 
accumulate in solid tumours due to 
the enhanced permeability and 
retention (EPR) effect. 
After sufficient accumulation of 
AuroShells (generally occurring 
12-24 hours post-infusion), the area 
is illuminated by an 808 nm laser 
causing the nanoparticles to heat 
and burning the tumour tissue. 
Averitt et 
al. [386] 
1997 
CYT-6091 for 
the treatment of 
27 nm citrate 
stabilised AuNP, 
In this formulation, antitumor agent 
TNF-α is less toxic, has decreased 
Paciotti et 
al. [191] 
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advanced stage 
nonresectable 
cancers 
surface functionalised 
with TNF-α and 
thiolated PEG 
circulation time, and evades RES 
uptake due to the surface 
PEGylation of the AuNPs. 
2004 
Libutti et al. 
[377] 2010 
Plasmonic 
phototherapy 
for the 
treatment of 
cardiovascular 
disease 
Allogenic stem cells 
containing gold-
coated silica 
nanoparticles 
AuNPs administered through a 
patch implanted into the artery are 
activated using NIR irradiation. 
The absorbed energy burns the 
surrounding tissues /atheroma. 
Kharlamov 
et al. [384] 
2010 
Targeted 
radiopharmaceu
tical treatment 
of prostate 
cancer 
EGCG-reduced 
radioactive 198AuNPs 
EGCG targets 67 KDa receptor 
protein (Lam 67R) overexpressed 
on cancer cells, allowing selective 
uptake in prostate cancer cells 
Shukla et 
al. [56] 
2012 
Photothermally 
active LiposAu 
NPs for the 
tumour ablation. 
100−120 nm gold 
coated liposomes 
Target-non-specific LiposAu NPs 
tuned to an absorbance range of 
750 nm are intravenously injected. 
Target site laser irradiated to kill 
cancer cells. LiposAu NPs are 
shown to degrade into smaller 
particles to allow their excretion. 
Rengan et 
al.[391] 
2015 
Table 7. Summary of the application of AuNPs as therapeutic agents. 
5.3 Gold nanoparticles as bioimaging agents 
The use of gold as an immunostaining agent was first documented in 1971 when Faulk and 
Taylor used antibody coated AuNPs to visualise specific antigens using TEM [392]. Relying 
on the ‘lock and key’ mechanisms of antibody-antigen interactions in combination with the 
high electron density properties of gold, immunolabelling methods have expanded with 
multiple labelling possibilities (using different sized AuNPs) [393], and adaptations have 
been made for visualisation using SEM [394, 395] and dark field microscopy [374]. 
The use of AuNPs as an alternative to iodine based contrast agents was discovered 
serendipitously by Wilhelm Röntgen in 1895 when taking an X-ray of a subject wearing a 
gold ring [396]. Gold, both in its nano and macro forms, exhibits high X-ray attenuation due 
to its high electron density [397, 398] (Fig. 21); however AuNPs offer additional enhanced 
permeability and retention effects inside tumour regions, unique SPR effects and are able to 
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be surface functionalised to target specific tissues or organs, making it possible to combine 
imaging with therapeutic treatment. X-ray computed tomography (CT) imaging creates 
detailed structural scans of the body by exploiting the natural variation in X-ray absorption 
between different tissues [399]. The use of traditional contrast agents for CT imaging 
(typically iodine based) has allowed contrast to be created artificially in areas where it does 
not naturally exist. However, the downfalls with iodine-based CT contrast agents include low 
retention time, nephrotoxicity, thyroid gland abnormalities and anaphylaxis [400-402]. 
Further, the use of AuNPs as contrast agents is not limited to CT scanning and can extend to 
optical coherence tomography [403] and photoacoustic tomography [404]. 
 
Fig. 21. CT images comparing Iopromide (commercial iodinated imaging agent) and AuNPs. 
Contrast agents are compared over a range of tube potentials (energy and intensity of the X-
ray beam) with AuNPs showing superior contrast in all conditions tested. Reprinted with 
permission from [405]. Copyright 2010 Elsevier Inc. 
With sufficient work on the efficacy of AuNPs as bioimaging agents in vitro, many groups 
are testing AuNP based imaging agents on animal models in vivo [66, 141, 184, 282, 401]. 
CT imaging of the liver is an important tool for the diagnosis, treatment and monitoring of 
cancer as it is a common site for secondary cancer presentation. However resolution of the 
livers microstructure is difficult, even with the use of conventional contrast agents [406]. 
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Specifically, iodinated contrast agents exhibit low levels of liver uptake, demonstrating the 
demand for target (tissue or organ) specific contrast agents. Sun and co-workers created 
AuNPs surface modified with heparin, a naturally occurring biomolecule with anticoagulant 
properties, to compare their performance with a commercial iodinated contrast agent. The 
heparin modified AuNPs displayed liver specificity [406, 407], allowing for differentiation of 
liver tissues and clear visualisation of vessels less than 1 mm in diameter. In contrast, the 
iodine based agent provided markedly (3.2 fold) less contrast. The mice received a dosage of 
200 mL of a 250 mg Au/kg solution in this study, as these AuNPs preparation were found to 
be biocompatible to human hepatocellular liver carcinoma (HepG2) cells to the levels of 100 
mg/mL [406]. The authors acknowledge that while promising, extensive cytotoxicity testing 
is necessary for the progress of this technology. 
Alternatively, researchers have used AuNPs to improve the short imaging window associated 
with iodinated CT contrast agents due to their low circulation times [401, 402]. By PEG-
coating AuNPs to elude RES uptake, when injected into rats the PEGylated AuNPs 
demonstrated an X-ray absorption coefficient 5.7 times higher than a commercial iodinated 
CT contrast agent, as well as a blood circulation time 4 hours longer. While this study noted 
accumulation of AuNPs in the spleen and liver, there was no appreciable toxicity seen for up 
to one month, nor was toxicity observed after conducting an MTT test on human 
hepatocellular liver carcinoma (HepG2) cells using concentrations of the particles higher than 
the expected therapeutic dose levels [401]. 
To demonstrate this point further, Au et al. tested the circulation time of PEGylated AuNPs in 
vivo using mice. After injecting the mice with either PEGylated AuNPs or an iodinated 
contrast agent, the mice were CT imaged immediately and after 6 and 24 hours. While 
PEGylated particles showed clear contrast which continued to the last time point of the 
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experiment at 24 hours, the iodinated contrast provided sufficient contrast immediately, 
failing at the subsequent 6 and 24 hour time points [408]. This study highlights the use of 
AuNPs for prolonged and delayed imaging of subjects which could be useful for real time 
imaging during procedures. 
The ability to combine cancer diagnostics and therapeutics into a single process is a goal 
currently pursued by many research groups [371, 374, 376, 378, 409]. By harnessing the SPR 
capabilities of AuNPs, the idea of imaging and delivering photothermal treatment using one 
diagnostic tool may become a reality in the near future. The research group led by El-Sayad 
employs gold nanorods of a chosen aspect ratio which strongly absorb and scatter light in the 
NIR region after surface modifying them with anti-epidermal growth factor receptor (anti-
EGFR) monoclonal antibodies. Due to the high expression of EGFR on the surface of 
malignant cells, the rods were observed to have >2-fold higher uptake by malignant cells 
(oral epithelial cell lines HOC 313 clone 8 and HSC 3) versus non-malignant cells (human 
epithelial cells (HaCaT). Because of the increased uptake of AuNPs and thus strong light 
scattering capability, the malignant cells were clearly visible using dark field microscopy. 
Furthermore photothermal treatment using an 800 nm laser required half the dose to kill the 
malignant cells as compared with non-malignant cells. Similar results were obtained using 
folic acid functionalised AuNPs to target epithelial cancer cells by Bhattacharya et al. [229] 
and bombesin functionalised AuNPs to target breast and prostate cancer by Chanda et al. 
[178]. 
Inspired by such promising results, Niidome and co-workers performed an in vivo study of 
PEGylated and CTAB stabilised AuNRs to determine their cytotoxicity and biodistribution 
after intravenous delivery into mice. Using human cervical cells (HeLa) the cytotoxicity of 
PEGylated AuNRs was found to be very low, with ~90% cell viability at doses of 0.5 mM in 
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contrast to the high cytotoxicity observed with CTAB stabilised AuNRs (which were only 
washed to remove free CTAB once). The group then injected the tail veins of mice with 
either PEGylated or CTAB stabilised AuNRs. After specific time points the animals were 
sacrificed, with their blood and organs collected and tested for gold content to determine the 
biodistribution of AuNRs. While CTAB stabilised rods were found primarily in the liver after 
30 minutes (~30% of injected dose), <10% of the injected dose was present in the blood. 
PEGylated AuNRs in contrast had prolonged circulation time with 54% of the injected dose 
found in the blood after 30 minutes. This level decreased over time, until being completely 
removed from circulation at 72 hours. At this time 35% of the injected dose was found inside 
the liver while only a small amount was detected in the other organs tested (lung, spleen and 
kidney) [282]. This demonstrates the importance of surface functionalisation in terms of 
achieving controlled biodistribution of AuNPs, while supporting the efficacy of PEG for 
evading RES uptake of AuNPs. In combination with PEGylation, targeted surface decoration 
of AuNPs could create tailored imaging and photothermal systems to treat various cancers. 
Bioimaging 
application 
AuNP Bioimaging advantages Reference 
Molecular 
imaging and 
photothermal 
cancer 
therapy 
AuNRs of 
aspect ratio 3.9 
conjugated with 
anti-EGFR 
monoclonal 
antibodies. 
AuNRs show higher affinity for 
malignant cells due to an 
overexpression of EGFR.  
Increased uptake and strong light 
scattering capability, allow malignant 
cells to be visualised using dark field 
microscopy. 
Huang et al. 
[374] 2006 
Targeted 
delivery of 
anticancer 
drugs, tumour 
imaging, and 
tumour ablation 
5 nm AuNPs 
functionalised 
with folic acid 
and various PEG 
backbones. 
AuNPs are preferentially taken up by 
ovarian cancer and myeloma cell lines 
which show over expression of folate 
receptors (FR).  
Bhattacharya 
et al. [229] 
2007 
CT imaging of 
the liver 
PEG-coated 
30nm spherical 
AuNPs 
PEGylated AuNPs demonstrate higher 
X-ray absorption coefficient and longer 
blood circulation time compared with 
traditional CT contrast agents. 
Kim et al.  
[401] 2007 
In vivo 
molecular 
CTAB stabilised 
AuNRs (aspect 
Bombesin AuNRs show increased 
affinity for prostate and breast cancer 
Chanda et al.  
[178] 2009 
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imaging for 
breast and 
prostate cancers 
ratio 3.1), 
conjugated with 
bombesin 
peptides. 
cells which show overexpression of 
gastrin releasing peptide receptors. 
CT imaging of 
the liver 
Heparin 
modified AuNPs 
Traditional iodinated contrast agents 
exhibit low levels of liver uptake, while 
heparin modified AuNPs display liver 
specificity to provide clearer 
visualisation. 
Sun et al.  
[406] 2009 
Long time scale 
CT imaging 
14, 18, and 21 
nm PEG-coated 
AuNPs 
AuNPs provided clear contrast for 4 
times longer than traditional CT 
contrast agents. Potentially important 
factor for real time surgical imaging. 
Au et al. 
[408] 2013 
Single cell 
imaging 
DNA modified 
42 nm spherical 
AuNPs with 
various 
PEGylation and 
peptide surface 
modifications to 
target specific 
cellular sites. 
SERS intensity of AuNPs allows live 
cell visualised of dynamic cellular 
changes which can employed for 
applications such as drug and stimulus 
response measurements. 
Kang et al. 
[410] 2015 
Table 8. Summary of the applications of AuNPs as bioimaging agents. 
6. Summary and outlook 
Overall, this Review has provided a critical analysis of different AuNPs synthesis methods, 
while assessing relevant biological studies to highlight emerging trends in AuNPs uptake and 
toxicity. Among different nanomaterials, AuNPs undoubtedly show some of the most 
interesting physico-chemical properties that make them useful for a number of biological 
applications including medical imaging [139, 141, 183, 184, 378], therapy [12, 53, 142, 179, 
369, 378, 390], diagnostics [55, 180, 190, 194, 195, 411], biosensing [70, 412, 413] as well as 
gene [188, 192, 414-416] and drug delivery [142, 186, 189, 191]. Some of the major driving 
forces for their consistent interest in biomedical applications are that AuNPs appear to be 
well tolerated in biological systems causing minimal cytotoxicity, while providing 
opportunities for facile surface manipulations as well as exhibiting interesting optical 
properties. A major focus of this review has been to ignite a critical discussion around the 
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influence of different physico-chemical properties of AuNPs on their biological activity. The 
ability to finely tune these properties of AuNPs by controlling the synthesis process puts great 
power in the hands of researchers by allowing them to tailor particles specifically for their 
intended purpose. While there seems to be some concerns about practical in vivo applicability 
of AuNPs due to potential metal accumulation in the body, such concerns have not been 
thoroughly validated through long-term in vivo studies. It is only recently that the importance 
of such studies has been recognised and research community has more seriously started to 
investigate the influence of various in vivo factors such as spontaneous protein corona 
formation on nanoparticles in response to in vivo exposure. In authors’ opinion, among 
various aspects of research involving use of AuNPs for nanomedicine, an in-depth 
understanding of dynamic biological corona formation on AuNP surface on their exposure to 
biological fluid, remains the cornerstone of achieving clinically translatable therapies. New 
knowledge gained from nanoparticle-protein corona dynamic interactions will not only lead 
the way forward for tailor designed AuNP-based in vivo therapies; they will also offer equally 
valuable opportunities to take in vitro applications of AuNPs such as diagnostics to a 
commercialisation stage. The authors foresee that the impact of such studies on in vitro 
applications is likely to be more significant, as bioaccumulation and long-term cytotoxicity 
issues of gold outside the body are of least concern. Further, while the versatility of AuNP 
usage for biological applications remains undeniable, the scientific literature regularly shows 
conflicting outcomes in regards to gold-bio interactions. To overcome this inconsistency, a 
set of guiding principles need to be developed so that only appropriate assays are used to 
assess the toxicity of AuNPs; careful assessment of surface corona is performed before 
correlating biological action to nanoparticle surface chemistry; and the change in surface 
chemistry of AuNPs is carefully considered on exposure to biological fluids, whether under 
in vitro or under in vivo conditions. Such guiding principles will allow researchers to be able 
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to predict the toxicity, uptake and action profile of AuNPs of different sizes, shapes and 
surface chemistry without necessarily warranting extensive testing. Overall, this Review has 
provided a critical analysis of different AuNPs synthesis methods, while assessing relevant 
biological studies to highlight emerging trends in AuNPs uptake and toxicity. The authors are 
hopeful that this review will ignite a critical discussion around new ways of assessing 
nanomaterial toxicity, while paying close attention to the influence of biological corona 
formed on the nanomaterial surface during their exposure to the biological world. 
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